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ABSTRACT
Many diseases, especially cancer, are not static, but rather can be summarized by
a series of events or stages (e.g. diagnosis, remission, recurrence, metastasis, death).
Most available methods to analyze multi-stage data ignore intermediate events and
focus on the terminal event or consider (time to) multiple events as independent.
Competing-risk or semi-competing-risk models are often deficient in describing the
complex relationship between disease progression events that are driven by a shared
progression stochastic process. In the first chapter, we propose a semi-parametric
joint model of diagnosis, latent metastasis, and cancer death and use nonparametric
maximum likelihood to estimate covariate effects on the risks of intermediate events
and death and the dependence between them. We illustrate the model using SEER
prostate cancer data.
In the second chapter, we focus on the adverse effect of younger diagnosis age
on cancer survival. We use a joint model with a shared gamma frailty term to in-
terpret the effect as a consequence of correlation between diagnosis time and the
post-diagnosis survival time. In the traditional analysis, diagnosis time is treated
as the time origin for a model of overall survival that fails to utilize the full infor-
mation leading up to diagnosis. Often the available covariates do not fully explain
the correlation between time-to-diagnosis and time-to-death calling for use of joint
modeling and frailties to extend the model. We show that the variance of the frailty
term and covariate effects can be estimated by a nonparametric maximum likelihood
method. Laplace transformation is used to derive likelihood contributions. The
x
model is applied to Michigan SEER breast cancer data.
In the third chapter, we compare dynamic treatment regimens from clinical trials
with multiple rounds of treatment randomization (sequential multiple assignment
randomized trials, SMARTs). Previously proposed methods to analyze data with
survival outcomes from a SMART use inverse probability weighting and provide non-
parametric estimation of survival rates, but no other information. We apply a joint
modeling approach here to provide unbiased survival estimates and as a mechanism to
include auxiliary covariates, treatment effects and their interaction within regimens.
We address the multiple comparisons problem using multiple-comparisons-with-the-
best (MCB).
Keywords: Disease natural history; Frailty model; Semiparametric regression;




The effects of clinical and demographic factors along with therapeutic interven-
tions on the overall survival time of patients with any disease is not a new problem
in survival analysis. Common methods of analysis include Cox proportional hazards
and frailty models. Situations where a certain event prevents others from being ob-
served (e.g. death due to other causes occurs before death from disease of interest)
have been studied extensively within the competing risks framework. However, there
is no agreed-upon procedure to model survival data where there are multiple time-
to-events of interest that make up the disease process. This dissertation presents
joint models to analyze multiple time-to-events in the observational (chapters II and
III) and experimental (chapter IV) settings.
One setting where multiple time-to-events of are of interest is cancer progression.
A cancer patient progresses from time of diagnosis, through various stages of cancer
(e.g. metastasis, remission, relapse) to death. Because these events are symptoms of
the same underlying disease, the times to each event are dependent on each other.
As a result, the entire process cannot be studied using conventional survival analysis
with a single time-to-event outcome. Our proposed methods for this setting are
motivated by SEER data discussed in chapter II and III of this dissertation. Another
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setting where analyses of multiple time-to-events are necessary is in the evaluation of
dynamic treatment regimens, where subsequent treatments in a regimen are assigned
based on an individual’s time-to-response to the initial therapy. This setting and our
proposed methods are discussed in chapter IV.
Chapter II is motivated by the SEER prostate cancer data which includes U.S.
315,722 men who were diagnosed with prostate cancer between 1988-2003. Age
at diagnosis, metastasis status, and overall survival time were recorded. In the
traditional analysis, diagnosis time is used as the time origin for a model with a single
time-to-event (i.e. survival time after diagnosis) and ignores disease information
leading up to diagnosis. Moreover, traditional analysis does not utilize time-to-
metastasis which is an important clinical outcome that may depend on treatment
at diagnosis (and thus cannot be used as a covariate). A framework that model
these three stages simultaneously is necessary. Thus, we propose a joint model using
non-parametric maximum likelihood estimator (NPMLE) to model the effects of
treatment and other covariates on time-to-diagnosis, latent time-to-metastasis, and
time-to-death while taking into account the dependence structure between them.
The difficulties of capturing latent dependence between breast cancer time-to-
diagnosis and subsequent survival time is the main theme of chapter III. In the
context of cancer studies, the age at which a patient is diagnosed with cancer can be
considered as the time-to-diagnosis. From SEER registry of breast cancer patients
in Michigan between 1973-2011, women diagnosed at younger ages (30-40 years old)
have lower survival rates subsequently compared to those diagnosed at older ages
(40-60, >60 years old). As demonstrated, current models do not adequately capture
this non-constant adverse effect of diagnosis age on breast cancer survival. A joint
model based on the one proposed in chapter II was not flexible enough to fit this
2
empirical observation from SEER data. A joint model using diagnosis age as one
of the covariates for time-to-death, besides requiring a restrictive assumption about
this age’s effect over time (e.g. constant or piecewise), still could not predict the
full magnitute of age’s adverse effect. We proposed relaxing the assumption made
in chapter II regarding parametrically related baseline hazards for different cancer
stages, and add a shared gamma frailty term to interpret the effect as a conse-
quence of correlation between diagnosis time and the post-diagnosis survival time.
We show the procedure to estimate both baseline hazards for diagnosis and death
non-parametrically. Using Laplace transformation to derive likelihood contributions
averaged over the latent frailty term, we estimated the variance of the frailty term
and other covariate effects by NPMLE. The proposed model’s ability to capture la-
tent dependence between the two stages is demonstrated via plots of post-diagnosis
survival conditioning on different time-to-diagnosis.
Recent methods to model dynamic treatment regimens with survival outcomes
from clinical trials with multiple rounds of treatment randomization (sequential
multiple assignment randomized trials, SMARTs) are described in chapter IV. Pre-
viously proposed methods to analyze survival data from a SMART include non-
parametric estimators and parametric models based on Cox proportional hazards
models. All use inverse probability weighting to arrive at the estimation of survival
rates, but the models do not provide any causal inference. Using the setting of a
SMART with two treatment stages, we present a joint model of time between the
first and second round of treatment randomization and the overall survival time
to provide a mechanism to quantify treatment auxiliary covariate effects and their
interaction within regimens. Furthermore, we demonstrate the joint model’s robust-
ness over previous methods for SMART in predicting dynamic treatment regimens’s
3
survival rates under the presence of interaction between auxiliary covariates and
treatments. Additionally, we address the issue of multiple comparisons for the infer-
ence concerning the dynamic treatment regimens within a SMART. Specifically, we
implement multiple-comparisons-with-the-best to address the issue of multiple com-
parisons between embedded dynamic treatment regimens in a SMART with survival
outcomes.
The concluding chapter summarizes the strengths and limitations of the pro-
posed joint models for observational SEER cancer data and SMART settings. The




A Joint Model of Cancer Incidence, Metastasis, and
Mortality
2.1 Introduction
In a natural cancer progression, patients may be diagnosed with local disease
and achieve remission for some time after treatment, potentially progress, develop
metastasis and succumb to the cancer. Others may be diagnosed at a later stage and
show metastasis at initial diagnosis. We focus on cancer diagnosis, metastasis, and
death as a progressive sequence of cancer events (Figure 2.1) and how to model overall
survival time accounting for dependence between time in each stage. Our motivating
example is data on prostate cancer from the Surveillance, Epidemiology, and End
Results (SEER) registry. The case file in SEER follows prostate cancer patients
from diagnosis to death or end of last follow up. SEER provides metastasis status
at time of diagnosis (i.e. whether cancer had metastasized prior to patients being
diagnosed). The exact time of onset of metastasis remains unobserved. Because the
SEER case file only includes subjects diagnosed with cancer, we make use of the
second SEER dataset with population counts, matched by race and age, from which
the case file originated. Although it is more straightforward to only focus on the
case file, we want to make use of the available population data to (1) account for
people who were not diagnosed with cancer and (2) gain information regarding the
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latent metastasis process which occurs before diagnosis. This requires a joint model
of cancer incidence, metastases and survival.
The model focuses on inferences and predictions of the cancer progression mech-
anism leading to cancer-specific death, treating other causes of death as nuisance.
Implications of this approach for clinical decision making and model extensions into
a competing risks framework are outlined in the Discussion.
As noted, the onset of metastasis is unobserved (latent) before the disease reaches
a measureable size; therefore if metastasis is present at the time of cancer diagnosis,
the onset must have occurred at some prior time point. Overall, metastases are the
cause of over 90% of cancer deaths (Mehlen and Puisieux, 2006). For cancers that
originate in a non-vital organ, such as prostate, virtually all deaths are caused by
cancer spread to other organs. Indeed, 99% of men with prostate cancer survive after
5 year (95% after 15 years). However, only 28% of those diagnosed with prostate
cancer that has metastasized survive to 5 years (American Cancer Society, 2016).
Thus our study tailors to settings where death-due-to-cancer can only occur as a
result of metastasis (Figure 2.1). We assume that if a patient was first diagnosed
without metastasis, metastasis occur at some subsequent point prior to death. For
the minor fraction of cancers where local growth can be lethal, such as brain cancer,
dependent competing causes of cancer death would require substantial additional






Figure 2.1: Diagram of cancer progression: Cancer diagnosis after metastasis ; diagnosis before
metastasis . Exact time of metastasis onset is unknown.
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As a result of the multi-stage nature of cancer, there are many issues that make
conventional survival analysis with a single time-to-event outcome inappropriate.
First, the occurrence of certain stages may prevent others from being observed (e.g.
metastasis may occur prior to cancer diagnosis, preventing observence of time-to-
diagnosis-without-metastasis). This censoring due to other events should be ac-
counted for when analyzing each time-to-event outcome. Second, part of the natural
disease progression may be latent and thus cannot be observed (e.g. metastasis on-
set). Third, the dependence between time-to-observable-events (e.g. diagnosis and
death) and the latent disease leading up to them (e.g. metastasis) make it difficult,
and potentially misleading, to separately model the outcomes. The treatment effect
has multiple causal paths, one of them being the effect on the risk of death through
the latent metastatic process.
In cancers where death can occur without metastasis (from local disease in a vital
organ), death and metastasis are semi-competing risks (Fine et al., 2001) and this
area has received considerable attention. Because of the non-identifiability issue from
competing risks, a full nonparametric solution is not available (Peng and Fine, 2007).
Many have combined the semi-parametric approach with a copula model (Nelsen,
1999) to account for dependent competing risks. Clayton copula (Clayton, 1978)
and bivariate survival models (Oakes, 1989) are popular choices for this approach.
Recently, Chen (2012) proposed using a semi-parametric transformational model
for the marginal distribution and a copula model for the joint distribution of time-
to-each-event. In our setting, since death due to prostate cancer can only occur
following metastasis but not vice versa, these events represent recurrent events that
are partially unobserved, rather than semi-competing risks.
Multi-stage models have been a popular tool (Andersen et al., 1991; Xu et al.,
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2010; Kalbfleisch and Prentice, 2011; Hougaard and Hougaard, 2000) where the sim-
plest non-trivial example is the illness-death model (Andersen and Keiding, 2002).
This method models the transition intensities between any two stages of the disease
process. However, the limitation of these transition intensities is that they only con-
sider two stages at a time rather than a joint progression process. This is usually
referred to as the “Markovian” assumption (Andersen et al., 1991). There are re-
cent developments to handle situations where the Markovian assumption is invalid
including a nonparametric estimation of the transition intensities (Meira-Machado
et al., 2006), the use of Gamma frailty (Xu et al., 2010), and a branch of shared-
frailty effect (Nielsen et al., 1992; Hougaard and Hougaard, 2000; Liu et al., 2004;
Govindarajulu et al., 2011).
To address the issue of latent stage, Hu and Tsodikov (2014b) proposed a semi-
parametric regression model that is based on Markov modulated processes with
non-parametric time transformation models in the setting of metastasis - recurrence
paradigm where they model time-to-recurrence as a marked-end-point. We extend
the model in Hu and Tsodikov (2014a) to a cancer process with more than two stages
that can be latent or observed, terminal or non-terminal. Using non-parametric max-
imum likelihood (NPMLE) (Tsodikov, 2003; Zeng and Lin, 2006; Chen, 2009), we
provide an estimating procedure for the effect of treatment and other covariates
on time-to-metastasis, time-to-cancer-diagnosis and time-to-death, while taking into
account the dependence structure between them.
In our data analysis example, there are deaths due to other causes. This presents
the issue of competing risks. There are two common approaches to address this issue:
Switch to cumulative incidence functions (Fine and Gray, 1999), or use copulas to
explain the dependence between potential competing risks. The former is not ideal
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because inference then depends on censoring, which is unpleasant to keep track of
since this would change with different populations and cause distributions. On the
other hand, because of the non-identifiability issue, defining a model based on cop-
ulas would depend on strong assumptions; thus we decided to perform a sensitivity
analysis to assess the effect of informative censoring (dependent risks) in our model.
In Section 2.2, we provide notation and model description (2.2.1), data structure
(2.2.2), counting processes (2.2.3), joint likelihood (2.2.4), score functions and es-
timating procedure (2.2.5), and asymptotic properties (2.2.6). In Section 2.3, we
use Monte Carlo simulations to verify the model’s performance and its robustness
against dependent censoring. In Section 2.4, we present an application to prostate
cancer using SEER data to demonstrate the model and its ability to handle issues
in multi-stage time-to-event data.
2.2 Methods
2.2.1 Notation and Model
We are interested in modeling data of cancer progression including diagnosis,
metastasis, and death. Let TU be the unobservable time-to-metastasis-onset; T
∗
1 and
T ∗2 be the potentially (due to censoring) observable times of diagnosis and death,
respectively. For clarity, we denote Z1 as the sets of covariates that affect all stages,
while Z2 refers to variables that start after diagnosis (e.g. for SEER analysis, Z1
includes race categories and Z2 includes metastatic status at diagnosis and treat-
ments). In the context of the joint model, part of Z2 (metastatic status) represents
a component of the joint response, and part (treatment) is treated as a covariate.
While formally a fixed covariate in the post-diagnosis submodel, treatment absorbs
future internal processes and implied decisions not measured in SEER data, and is
potentially subject to unmeasured confounding because the treatment decision at
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disgnosis may be based on unmeasured clinical characteristics. We recognize the
potential pitfall of including internal covariates (Kalbfleisch and Prentice, 2011) and
advocate caution interpreting treatment effects. Let Z = (Z1∪Z2) be the covariate
vector.
Hu and Tsodikov (2014b) provide mechanistic justification for use of a common
baseline hazard across hazards to different stages as a surograte of the same un-
derlying disease pattern driving the time to diagnosis, metastasis and death. The
assumption can be understood as a single nonparametrically specified time scale for
all disease-related events.
We relax this assumption of a common hazard by creating additional parameters
δ1 and δ2 for the nonparametric baseline cummulative hazard function Ht (instan-
taneous hazard ht). Denote the cummulative hazards for metastasis, diagnosis, and
death at time tx respectively as Hx, H
δ1
x , and H
δ2
x . Thus, the analogous instanta-
neous hazards are hx, δ1H
δ1−1
x hx, and δ2H
δ2−1
x hx. This parameterization can flexibly
account for the various stretching and shrinking in baseline hazards for different can-
cer events, while saving us the computational burden of estimating multiple baseline
hazards nonparametrically. Using 1(·) as an indicator function and a series of Cox
proportional hazards models, the hazards for cancer events are parameterized as
follows:
• Time-to-metastasis-onset λU(tu|Z, T1) = hu(η1(tu < T1) + η̃1(tu ≥ T1)),
• Time-to-diagnosis λ1(t1 | Z, TU) = δ1Hδ1−11 h1θµ1(t1≥Tu),
• Time-to-death λ2(t2 | Z, TU , T1) = δ2Hδ2−12 h2γ1(t2 ≥ max{Tu, T1}),
where η = eβ
T
η1
Z1 , η̃ = eβ
T
η Z , θ = eβ
T
θ Z1 , µ = eβ
T
µZ1 , and γ = eβ
T
γ Z .
Let β = [βη, βθ, βµ, βγ, δ1, δ2] be the coefficients vector. Let Sx(t|·) = e−
∫ t
0 λx(s|·)ds
and fx(t|·) = λx(t | ·)Sx(t | ·) be the corresponding conditional survival and density
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functions, respectively, for hazard functions λx(t | ·).
2.2.2 Observed Data Structure
Let V ∗ be the censoring time, independent of (T ∗1 , T
∗
2 ) given Z; and ξ be the
maximum follow-up time of the study. For each subject i = 1, 2, ..., n in the study,
we observe {T1i, T2i, ∆−1i,∆+1i,∆−2i,∆+2i, Zi}, where T1i = min(T ∗1i, V ∗i , ξ) is the time-




i , ξ) is the time-
to-second-observable-event (death or censoring); ∆−1i = 1(T1i = T
∗
1i, TUi > T1i) is
an indicator of diagnosis without metastasis; ∆+1i = 1(T1i = T
∗
1i, TUi ≤ T1i) is an




1i is an indicator of
observing death after diagnosis without metastasis (i.e.. metastasis occurs some




1i is an indicator of
observing death after diagnosis with metastasis.
2.2.3 Combine population risk-set and cancer events
SEER case data only include subjects who would eventually be diagnosed with
cancer. This is sufficient if we are only interested in estimating the risk of death
assuming everyone was diagnosed with cancer. However, we are also interested in
estimating the risk of being diagnosed with cancer in the general population. Thus,
we need to combine a separate dataset that tracks the size of the at-risk population
from which our cancer cases originate. This essentially provides life-table data for
cancer diagnosis, followed by subject-level data for cancer death.
Figure 2.2 outlines how we use population counts as the risk set for diagnosis
events. Let Y1i(t) = 1(t ≤ T ?1i) and N1i(t) = 1(T ∗1i < t) denote subject i’s risk process
and counting process for cancer diagnosis, respectively. Let Y2i(t) = 1(T1i < t < T2i)
and N2i(t) = 1(T
∗















Figure 2.2: Using population counts as risk set for diagnosis events. Z1 = race; Ywhite(t), Yblack(t),
and Yother(t) are population counts by race at age t; dN1i(t) denotes the counting
process of breast cancer diagnosis for subject i from the population; Y2i(t) denotes
subject i being at risk of death due to breast cancer; dN2i(t) is the counting process for
this death event.
due to cancer. Since our prostate cancer diagnoses are from U.S. men between 1988-
2003, we use counts of the male population during the same time period and in the
same geographic location, stratified by Z1, to define the risk-set for cancer diagnosis.
Let Yz1(t) denote the population counts for subset that takes value z1 for covariate
set Z1. Instead of summing up n cancer subjects, we sum up all categories of Z1
to get the whole at-risk population. Similarly, denote Nz1(t)=
∑
i:Z1i=z1
1(T ∗1i < t) as
the counting process for the number of diagnoses from subgroup z1.
2.2.4 Likelihood Construction
We integrate out time-to-metastasis-onset, TU , by the appropriate time interval
since the exact time is not observable. Denote fxfyfz(tx, ty, tz) the joint probability
of the sequence of events x, y, and z occuring at times tx, ty, tz, respectively. The
contribution of each subject to the likelihood falls into one of the following five
scenarios (see Supplementary Materials A.1 for derivation):
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This joint probability can be written as L∗1 = L1 ·L̃1, where L1 is the probability
of observing up to time-of-diagnosis:
L1(t1) = SUf1(t1, t1) = δ1Hδ1−11 h1θe−H1η−H
δ1
1 θ.
(2) Subject is diagnosed without metastasis at t1, may or may not have metastasis
























where µ = 1− µ. Alternatively, L∗2 can be rewritten as L1 · L̃2.






















































Alternatively, this can be specified as L∗4 = L3 · L̃4.
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2ilog(L∗1i) + ∆−1i(1−∆−2i)log(L∗2i) + ∆+1i∆+2ilog(L∗3i)+
∆+1i(1−∆+2i)log(L∗4i) + (1−∆−1i −∆+1i)log(L5i)
=
{
















[logΘ1i(Ht, β) + logdHt] dN1i(t)− Y1i(t)Θ1i(Ht, β)dHt+
[logΘ2i[Ht, β, t1] + logdHt] dN2i(t)− Y2i(t)Θ2i[Ht, β, t1]dHt. (2.2)




2i as the quantities in each line of equation (2.1), it is easy to see




2 are the contribution
from the subsequent time segments between diagnosis and death.
This is re-written using counting processes in equation (2.2), where Θ1i(Ht, β)dHt
is the hazard of subject i being diagnosed at time t and Θ2i(Ht, β, t1)dHt is the hazard
of subject i dying of cancer, given diagnosis at time t1 with (Met+) or without (Met-)
















































t γ, after Met+
(2.4)
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(see Supplementary Materials A.2 for details of derivation).
For ease of notation in the rest of this paper, we shorten Θ1(Ht, β) and Θ2(Ht, β, t1)
to Θ1(t) and Θ2(t), respectively.
As discussed in section 2.2.3, we use population counts to account for the whole
risk-set that includes people who never had prostate cancer. Let Z1 denotes the
set of covariates available at the population level before diagnosis. We stratified all
subjects by Z1 and set Θz1(t) = Θ1i(t) where Z1i = z1. Once diagnosis occurs, SEER
follows individual subjects; thus we have notation i for subject-level data. The joint






[logΘz1(t) + logdHt] dNz1(t)− Yz1(t)Θz1(t)dHt+
n∑
i=1
[logΘ2i(t) + logdHt] dN2i(t)− Y2i(t)Θ2i(t)dHt. (2.5)
2.2.5 Nonparametric maximum likelihood estimator (NPMLE)
Score Functions








































































dN(t), Y (t), d̂HNA(t) → Θ1(t),Θ2|1(t)





Use full-path H(t) to
update ω(t,Hξ, β)
Figure 2.3: Calculate d̂H(s) for all event time s, repeat until convergence.
Estimation Procedure
We set equations (2.7) to zero and solve for the NPMLE of the jump in the baseline










Yz1(x)ωz1(Hξ, x, β)Θz1(x) +
n∑
i=1
Y2i(x)ω2i(Hξ, x, β, t1i)Θ2i(x)
, (2.8)





, using the following martingales
dMz1(t) = dNz1(t)− Yz1(t)Θz1(t)dHt, for z1 ∈ Z1
dM2i(t) = dN2i(t)− Y2i(t)Θ2i(t)dHt, for i = 1, 2, ..., n.
Denote t = {t(1), t(2), ..., ξ} as the set of unique time, with ξ being the last time
point, where event occurs in our data. Maximization of the log-likelihood with
respect to H(t) and β simultaneously is done using a profile likelihood approach and
an iterative reweighting algorithm (Chen, 2009) as follows:
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1. Start with candidate β?, weight ω(0)(t) = 1 and d̂H
(0)
(t) = Nelson-Aalen esti-
mator.
2. As illustrated in Figure 2.3, repeat these steps until convergence of d̂H(t):
- Use d̂H
(0)
(x) to calculate Θ
(0)
z1 (x),∀x ∈ t.
- Use Θ
(0)
z1 (x) and ω
(0) and eq. (2.8) to calculate d̂H
(1)
(x). With the weight
fixed, the right hand side of eq.(2.8) only depends on prior jumps H(t),
∀t < x.
- Sequentially do (b) along all x ∈ t to get full path Ĥ(1).
- Use full path Ĥ(1) to update weights ω(1).
3. Calculate log-likelihood `pr(β
?, Ĥ) using eq.(2.5).
4. Repeat step (1-4) to search β̂ = arg max
β
`(β).
Standard errors are estimated using the Hessian of the profile log-likelihood. See
Supplementary Materials A.4 for justification.
2.2.6 Asymptotic properties
Martingale properties












































which are both martingales at the true model (see Supplementary Materials A.3 for
proof).
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Consistency and weak convergence
Consistency and weak convergence result of the NPMLE Ω̂ = (β̂, Ĥt) is adapted
from Hu and Tsodikov (2014a). Assuming regularity conditions hold,
1. With probability one, β̂ converges to β0, Ĥt converges to H
0
t uniformly in the
interval [0, ξ], where H0t , β
0 are the true values of Ht, β.
2. n1/2{β̂ − β0, Ĥt − H0t } converges weakly to a zero-mean Gaussian process.
In addition, nET (In)−1E converges in probability to the asymptotic variance-
covariance function of the linear functional n1/2
{∫ ξ
0
aT (β̂ − β0) + b(t)T (Ĥt −H0t )
}
,
where a is real vector, b(t) is a function with bounded total variation in [0; ξ],
ET = (aT , BT ) where B is a vector of the values of b at the jumps of Ĥ, In is
the negative Hessian matrix of the observed log-likelihood function with respect
to Ω̂.
2.3 Simulation Studies
2.3.1 Different baseline hazards and sample sizes
We performed Monte Carlo simulations using R software to assess the proposed
methodology. For each scenario, 1000 repetitions with sample sizes 1000 and 2000
were performed. The parameters were set as follow: Each scenario included covari-
ates Z1 ∼ Bern(0.5), Z2 ∼ N(2, 0.5), and an increasing baseline hazard following a
Weibull(2, 2) distribution. Baseline hazard transformation is set at δ1 = 0.8 and δ2 =
1.5. Time-to-metastasis-onset, time-to-diagnosis, and time-to-death were generated
under Cox proportional hazards using parameters βη = [1.5, 0.9], βθ = [−0.6, 0.5],
βµ = [1, 1.2], βγ = [1.6,−0.7, 0.4], and are rounded to 2 decimal places.
Independent censoring time followed a uniform distribution U(1.5, 3) for the in-
creasing hazard, which yielded approximately 20% censoring before the first event
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Table 2.1: Simulation result: Increasing baseline hazard
Metastasis Diagnosis Death Ht transform
N Statistics βη1 βη2 βθ0 βθ1 βµ0 βµ1 βγ0 βγ1 βγ2 δ1 δ2
True 1.5 0.9 -0.6 0.5 1 1.2 1.6 -0.7 0.4 0.8 1.5
1000 Bias 0.03 0.00 .01 0.02 0.09 -0.02 0.04 -0.01 -0.01 0.01 -0.01
ESE 0.24 0.12 0.11 0.20 0.61 0.51 0.42 0.10 0.08 0.19 0.21
ASE 0.23 0.11 0.11 0.20 0.55 0.45 0.40 0.10 0.08 0.16 0.19
CP 92 91.8 93.8 92.4 93.2 94.3 91.8 95.7 95.3 88.4 88.7
2000 Bias 0.03 0.00 .01 0.01 0.06 -0.04 0.03 -0.01 -0.00 0.00 -0.02
ESE 0.16 0.08 0.07 0.14 0.41 0.33 0.29 0.07 0.05 0.11 0.12
ASE 0.16 0.08 0.08 0.14 0.39 0.31 0.29 0.07 0.06 0.11 0.13
CP 94.5 94.3 96.7 94.3 94.9 93.2 92.7 94.9 95.6 93.8 93.6
ESE: empirical standard errors based on 1,000 estimates
ASE: average of estimated standard errors
CP: 95% Coverage Probability
(diagnosis) and 30% censoring before the second event (death). The convergence
criterion was set at 10−5 for change in baseline hazard estimation and improvement
in the full likelihood.
The simulation results are summarized in Table 2.1. The iterative reweighting
algorithm works well for both scenarios of increasing and decreasing baseline haz-
ards (Weibull(0.5, 2), results not shown). The log-hazard-ratio estimates for co-
variate effects on time-to-latent-metastasis, time-to-diagnosis, and time-to-death are
almost unbiased at sample size n=1000 and get more accurate with larger sample
size n=2000. The empirical standard errors (ESE) are close to the mean of estimated
theoretical errors (ASE), which validate the performance of the variance estimators.
Coefficient estimators improve with increasing sample size as the estimated variances
decrease and 95% confidence intervals get narrower. The 95% coverage probabilities
for all coefficient estimators remain as expected for both sample sizes.
Estimates for baseline hazard transformation δ1 and δ2 are also accurate in terms
of small bias and consistent standard error estimation. The 95% coverages for these
parameters slightly underperformed at sample size n=1000, and improved to the
expected probabilities at n=2000.
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2.3.2 Informative censoring
We performed sensitivity analyses to assess the performance of the estimating
procedures and prediction function in the presence of time-dependent covariates and
dependent censoring. The simulated variables are similar to the SEER example data
as follows: Z1 ∼ Unif(1, 3) are 3 race indicators, Z2 ∼ Unif(1, 4) are 4 treatment
indicators . Baseline hazard follows Weibull(2, 10) distribution and δ1 = δ2 = 1.
For the independent censoring scenario, censoring time V ? ∼ Unif(0, 30) results
in 15 % censored before diagnosis and 30 % censored before death. For the de-
pendent censoring scenarios, we use the following copula for bivariate survival data:





, S2 and SV are survival
functions for death-due-to-prostate-cancer and death-due-to-other-causes (i.e. cen-
sored events) respectively. Thus, smaller ρ corresponds to higher dependence. This
simulation was run 1000 times at sample size 500.
Table 2.2: Simulation result: Dependent censoring. LHR = log hazard
ratio, CP = 95 % coverage probability
LHR for overall survival time (γ)
True 0.9 0.5 0.6 -0.6 -2 -1.4
Independent CP(%) 91.9 92.7 93.7 93.3 90.5 92.9
ρ = 5 CP(%) 91.1 95.3 93.7 92.1 90.7 92.9
ρ = 2 CP(%) 91.3 90.9 92.8 91.9 90.2 93.4
ρ = 1 CP(%) 90.5 92.3 90.0 92.1 89.6 90.2
ρ = 0.5* CP(%) 86.3 86.5 87.5 92.7 86.5 90.9
* smaller ρ corresponds to higher dependence
Table 2.2 shows the estimated log-hazard-ratios (LHRs) for overall survival time
(LHRs for time-to-metastasis and time-to-diagnosis are mostly unaffected, see Sup-
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plementary Materials A.5.2). In simulations where the dependence is moderate,
LHRs and standard errors are accurately estimated with finite sample size. This
performance, however, is effected by highly correlated censoring, In our most ex-
treme case (ρ = 0.5), we see some deviation from the normal 95% coverage for 5
out of 16 estimated coefficients. Even then, their worst coverage fluctuates down
to around 86%. A full-fledged dependent competing risks analyses is needed under
stronger dependence.
2.4 Application to SEER prostate cancer data
2.4.1 Data
We applied our proposed model to the motivating setting of prostate cancer using
a case file and population-at-risk counts available from the SEER registry. The
proposed model in its current specification (Figure 2.1) is tailored to this disease since
virtually all deaths from prostate cancer occur after the cancer has metastasized.
SEER, controlled by the National Cancer Institute, registers yearly incidence and
population data on various cancers in the U.S. starting from time of diagnosis. Figure
2.4 outlines some summary statistics for the following 2 datasets:
SEER population data: A large part of the population at risk was missing
since the incidence dataset only followed subjects who were diagnosed with cancer.
Therefore, we used population counts from which the cancer cases originated (i.e.
U.S. male population age 50-85 between 1988-2003) stratified by race, gender, age,
and year as the risk set of cancer diagnosis (Yz1(t) in eq.2.5). Although it is possible
to focus only on the case file starting from diagnosis, important information regarding
the latent metastasis process which occurs before diagnosis would be lost.
SEER incidence data: SEER case data provides race, gender, age, metastasis
status at diagnosis, and subsequent survival time of men who were diagnosed with
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Figure 2.4: SEER population and prostate cancer case data (USA, 1988-2003).
Population data: #males from US
-By age (50, 51, ..., 84)





b) Age < 50 or > 84 (n=17,689)
c) Diagnosis pre-1988 (n=33,530)
Cases analyzed
(n=315,722)
94% diagnosed with no metastasis 6% diagnosed with metastasis
Race: 83% White, 12% Black, 5% Others
Among 295,779 diagnoses:




Race: 75% White, 24% Black, 1% Others
Among 19,943 diagnoses:




Deaths (n=15,337) Deaths (11,303)
prostate cancer between 1973-2003. Out of all recorded prostate cancer diagnoses in
this time period (n=520,111), we concentrated on men between the ages of 50-84.
Subjects with unknown race, age, or treatment were removed under the assumption
of missing at random (n=315,722 remained).
Besides clinical variables, another factor that could potentially confound the effect
of treatment on survival is the use of prostate-specific antigen (PSA) screening which
began around 1988. The benefits of PSA screening are still debatable since it can
result in overdiagnosis (i.e. detection of disease that would not become symptomatic
during a patient’s lifetime in the absence of screening). Overdiagnosis can positively
affect the overall survival from diagnosis under screening compared to no screening
prior to 1988 (largely an artifact). To avoid confounding, we focused on cases with
diagnosis after 1988. Amongst these men, 94% were diagnosed without metastasis
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and 6% were diagnosed with metastasis. From 315,722 cancer diagnoses, 26,640 were
recorded to die from prostate cancer by 12/31/2003. Deaths from other causes and
those alive at the end of study were censored.
Metastasis status has a clear effect on treatment distribution. Radiotherapy and
surgery (prostatectomy) were the most popular treatment options for patients diag-
nosed without metastasis. 29% received no treatment, 36% received radiotherapy,
33% had surgery, and 2% had a combination treatment of radiotherapy and surgery.
On the other hand, most patients who were diagnosed with metastasis opted out of
all treatments: 80% received no treatment, 19% received radiotherapy, and the rest
received surgery.
Note that unlike race, treatments are time-dependent (zero prior to diagnosis and
thus only affect subsequent time intervals between diagnosis and death). These spec-
ifications can easily be accommodated by taking race as a covariate Z1 in the hazard
of initial diagnosis λ1(t|Z1). For patients who were diagnosed with local cancer (no
metastasis), treatment are time-dependent covariate Z2 effecting subsequent hazard
of metastasis λU(t|Z1, Z2). Because treatment are assigned dynamically based on
response to prior therapy, special care has to be made to interpret the treatment
effects on overall survival time. Beside the main treatment indicators, we add inter-
action terms with metastasis-status-at-diagnosis to account for the potential varying
treatment effect due to the patient’s underlying disease process.
2.4.2 Results
The estimated log-hazard ratios (LHR) for time-to-diagnosis, metastasis, and
death are summarized in Tables 2.3, 2.4, and 2.5. These LHR’s denote instanta-
neous relative risks with respect to the baseline group of white men who did not
receive treatment (i.e. elected to wait after cancer diagnosis). A positive coefficient
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signifies higher risk and thus a shorter time to event. The risk of metastasis (Table
2.3) changes at point of diagnosis (due to introduced interventions). Similarly, the
risk of being diagnosed of cancer (Table 2.4) increases in all races once metastasis
occured.
We found evidence of differences in the baseline hazards of three cancer stages
beyond proportionality. Once we estimated the baseline hazard for metastasis events,
the baseline hazards for diagnosis and death were estimated by taking exponent 1.66
and 1.02, respectively. This also demonstrate our model’s improvement for relaxing
the common baseline hazard assumption made in Hu and Tsodikov (2014a,b).
We found evidence of difference in baseline hazards of metastasis and diagnosis
beyond proportionality. Once we estimated the baseline hazard for metastasis events,
the baseline hazards for diagnosis was estimated by taking exponent 1.66 (P<0.001).
There is no evidence of change beyond proportionality for baseline hazard of death
(P=0.27). This also demonstrate our model’s improvement for relaxing the common
baseline hazard assumption made in Hu and Tsodikov (2014a,b).
Race and treatment were significantly associated with time-to-metastasis. White
men were found to have lower risk of metastasis overall compared to same-age
black men (LHR=0.08, P<0.01) and same-age men from other races (LHR=0.23,
P<0.001). For patients diagnosed with prostate cancer but with no metastasis,
treatment affected subsequent time-to-metastasis. Compared to no treatment (i.e.
waiting), surgery (radical prostatectomy) by itself did not have any statistically
significant effect (P=0.16). Radiotherapy alone and in combination with surgery in-
creased metastasis (LHR=1.97, P<0.001). Similar effects of surgical removal of the
primary tumor increasing risk of metastasis have been reported in cancer literature
(O’Reilly et al., 1994; Smolle et al., 1997; Biki et al., 2008; Neeman and Ben-Eliyahu,
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Table 2.3: SEER prostate cancer analysis: Time-to-metastasis-onset
LHR before diagnosis (βη)
Covariate Estimate SE P-value
ZBlack 0.08 0.03 <.01
ZOther 0.23 0.05 <.001
LHR after diagnosis (βη̃)
Covariate Estimate SE P-value
Intercept 4.03 0.04 <.001
ZSurgery 0.44 0.31 0.16
ZRadiotherapy 0.81 0.10 <.001
ZCombo 1.97 0.32 <.001
Table 2.4: SEER prostate cancer analysis: Time-to-diagnosis
Baseline hazard transformation
Parameter Estimate SE P-value
δ1 1.66 0.001 <.001
LHR before metastasis (βθ)
Covariate Estimate SE P-value
Intercept 4.53 0.02 <.001
ZBlack 0.42 0.01 <.001
ZOther 0.60 0.01 <.001
Change to LHR after metastasis (βµ)
Covariate Estimate SE P-value
Intercept 2.95 0.02 <.001
ZBlack 0.81 0.05 <.001
ZOther 0.41 0.07 <.001
Table 2.5: SEER prostate cancer analysis: Time-to-death
Baseline hazard transformation
Parameter Estimate SE P-value
δ2 1.02 0.02 0.27
LHR after diagnosis and metastasis (βγ)
Covariate Estimate SE P-value
Intercept 6.78 0.10 <.001
ZBlack 0.10 0.02 <.001
ZOther -0.45 0.04 <.001
ZSurgery -1.72 0.15 <.001
ZRadiotherapy 0.09 0.02 <.001
ZCombo -1.82 0.41 <.001
1Local ∗ ZWaiting 1.52 0.06 <.001
1Local ∗ ZSurgery 0.28 0.29 0.33
1Local ∗ ZRadiotherapy -0.46 0.11 <.001
1Local ∗ ZCombo 0.11 0.49 0.81
LHR: Log hazard ratio versus reference group (white men who elected “waiting” at diagnosis). SE: Standard
error
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2013) and could be overlooked in other models that do not account for the latent
metastasis process. This may also be due to a confounder in the physicians’ decision
to perform surgeries only on more severe prostate cancer diagnoses or support the
theory that removing the primary tumor along with its foreign antigens weakens the
signal for the immune system’s attack, making other body parts more susceptible to
metastasis.
The risk of being diagnosed with prostate cancer differs by race. In the U.S.
population of men older than 50 years, white men had slightly lower risk compared
to same age black men (LHR=0.42, P<0.001) and men from other races(LHR=0.60,
P<0.001). The occurence of metastasis before diagnosis also quickened time-to-
diagnosis: This risk increased among white men (LHR=2.95, P<0.001), more among
black men (LHR = 2.95 + 0.81, P<0.001), and most among men of other races (LHR
= 2.95 + 0.41, P<0.001).
The risk of death started after diagosis and metastasis occured. For patients who
were diagnosed after metastases, surgery was found to significantly lower risk and
prolong overall surival time (LHR=-1.72, P<.001). A combination of both surgery
and radiotherapy was also beneficial (LHR=-1.82, P<0.001). Radiotherapy by itself
slightly lower the survival rate but the effect was small (LHR=0.09, P=<0.001).
For patients diagnosed prior to metastasis, we include interaction terms to account
for the effect of subsequent treatment assigned dynamically after response to initial
treatment. Among these patients, those assigned “waiting” and radiotherapy at
diagnosis were found to have differences in risk-of-death compared to those diagnosed
with metastasis (LHR=1.52, P<0.001; LHR=-0.46, P<0.001).
Due to the potential confounder of physician’s subjectivity and other unaccounted
covariates, the interpretation of treatment difference may suffer if interpreted as
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treatment effect in the context of a randomized clinical trial. However, if we are
willing to assume that treatment is given based on observation of the covariates
included in the model, is a function of these covariates only, and ignore the extent
to which treatment depends on unobserved characteristics that are not controlled in
the model, then the model provides rough estimates of the treatment effect. Since
this is observational registry data, the treatment effect is interpreted with caution.
If we adopt the view that there are unaccounted covariates that influence treat-
ment choice, then we can use treatment as a surrogate for these covariates. This
means we do not interpret the treatment coefficients as purely the treatment effect
as in a clinical trial, but as an indication that perhaps more aggressive treatment
is given to patients that are worse off. Then by adjusting for treatment, the other
covariates would also be adjusted for in the model.
Beside race and the use of PSA screening, there are other potential confounders
that could bias treatment effects which were not captured in our model. One such
variable is the tumor grade (i.e. level of differentiation of tumor cells). There is a
biological concensus that tumors containing well-differentiated cells are less aggres-
sive due to the close resemblance of these cells to normal cells. Another factor that
could not easily be captured is the doctor’s decision in treatment choice which may
reflect disease severity (not captured by stage), experience, and patient decision. For
the purpose of treatment comparisons, statistical models assume similar represen-
tation of patients in each treatment group; however, this may not be the case in
reality. Physicians usually recommend more aggressive treatments when patients are
diagnosed with more advanced disease status and are young and healthy enough to
endure it. Treatment regimens may also change when a patient’s condition declines,
improves, or experiences side effects. Currently SEER data does not include more
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Figure 2.5: Fitted plot: Survival estimates for time-to-diagnosis. Proposed model (dotted lines,
eq.2.11) closely matches Kaplan-Meier (KM) estimates (solid lines).
clinical information to adjust for this subjectivity or changing treatment regimen.
2.4.3 Predicted Survival Rates
From our fitted model, we can derive closed-form formulas to predict the time to
each disease stage. This carries clinical significance because these survival rates could
be used to inform treatment decisions at each time point for future patients diagnosed
with prostate cancer. In this section, we derive the formulae for survival probabilities
at time t for diagnosis and death in the SEER example. These predicted survival
rates were compared against the empirical survival rates to validate our proposed
model. The survival probability for latent metastasis is not shown since we do not
have empirical time-to-metastasis-onset in SEER data to compare against.














Figure 2.5 plots the Kaplan-Meier (KM) curve and predicted survival rate for
prostate-cancer diagnosis in each racial group (eq. 2.11). Note that all the survival
probabilities are very close to 1 because we used the full US male population ages
50-84 as the risk-set, which is much larger than the size of the incidence dataset. This
figure validates the estimating procedure since the predicted and empirical survival
rates match closely for white and black men. There is a slight deviation between
the predicted survial rates and empirical KM curve amongst men from other races,
which could be due to the relatively much smaller sample size in this group compared
to white or black men.
The conditional survival rate given time-of-diagnosis can be derived and used
to compare how different treatments affect time-to-death among those that were
diagnosed with cancer at the same time. This conditional survival rate is derived
from L?2/L1 (section 2.2.4), which gives:








u )du+ e−η̃(H2−H1). (2.12)
Figure 2.6 compares the survival rates estimated from our proposed model (eq.
2.12) for death due to prostate cancer, conditioning on diagnosis time at 70 years old,
with the empirical Kaplan-Meier curve. We plot the subset of white men who received
no treatment (waiting), surgery, or radiotherapy. There were not enough events
recorded for combination treatment once we stratified by diagnosis time (only 2 %
received this type of treatment overall, 15 deaths recorded from 214 patients who were
diagnosed at age 70). The validity of the prediction function was further confirmed
via simulations that resemble the SEER setting but with equally distributed sample


































Figure 2.6: Fitted plot: Survival estimates (dotted lines, eq. 2.12) and empirical Kaplan-Meier
curves (solid lines) for death from prostate cancer among men who were diagnosed at
70.
2.5 Discussion
We presented an NPMLE estimator and proposed a model that simultaneously
estimated time to different events, where events were both latent and observable.
We relaxed the assumption of one common baseline hazards at different stages. The
two power parameters allow for flexible changes in baseline hazards of metastasis,
diagnosis, and death. Moreover, because we estimated only one baseline hazard
non-parametrically, our model was still more efficient compared to cause-specific
models. In the likelihood, the latent disease event is integrated within the appropriate
time interval anchored by observed events. The non-parametric baseline hazard and
covariate effects are iteratively estimated using a weighted Breslow-type estimator
derived from the score function. We verified the performance of this estimating
algorithm through Monte Carlo simulations at two sample sizes and types of baseline
hazards. Application of the proposed model to SEER prostate cancer cases among
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U.S. men ages 50-84 revealed different ways through which treatments ultimately
affected overall survival.
Our model differs from existing methods in that it can flexibly describe the re-
lationship between outcomes in multiple stages beyond the fact that one outcome
can prevent another from being observed. In SEER analysis, we specified that can-
cer death occurs after metastasis. This dependence can be even more nuanced by
specifying, for example, that the quickness by which metastasis occurs affects how
quickly death subsequently occurs. In cancer studies, where it is intuitively and bi-
ologically plausible that the “competing” stages are dependent, our model offers a
convenient way to summarize these effects compared to existing methods such as cu-
mulative incidence functions in a competing risk model or transitional intensity in an
illness-death model. Moreoever, the alterable components in the proposed model’s
stage-specific hazards and incorporation of time-dependent covariates allow for easy
adaptability to reflect covariates’ effects on different parts of the disease process.
Traditional methods also fail to explicitly model the time-to-a-latent-event. In
certain diseases, these latent outcomes may carry significant quality-of-life impor-
tance. Therefore, knowing how covariates affect these unseen events is sometimes as
important as studying the observable outcomes. Our current model is equipped to
infer this and incorporate scenarios where the event is partially missing in a subset
of the population.
The model focuses on a mechanistic description of cancer progression leading to
cancer-specific death. Its clinical value lies in the ability to study treatment and
other effects on the biological process, and the ability to predict the latent process
given clinical information available on the subject. This prediction can be dynami-
cally updated as more information becomes available in the course of subject’s life
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pre-diagnosis, diagnosis and subsequent follow-up. At the same time, there are lim-
itations in the clinical utility of this model. In particular, studying the potential
progression of cancer for a subject who died from other causes carries limited clini-
cal relevance. Other causes of death were treated as a nuisance in this paper. The
model’s extension to a competing risks framework is an interesting future develop-
ment that would allow better characterization of clinically relevant effects and poten-
tial exploration of possible association between cancer of interest, and its treatments,
and the risks of comorbidities and death due to other causes.
Currently, the earliest event of interest in our model is metastasis (or diagnosis if
it happens prior). We recognize that there is a disease-free period before a tumor is
initiated. However, modeling this process means making assumption about covari-
ates that are never observed. Our model addresses the challenge of latent variable
time-to-metastasis because this is observed indirectly via metastasis status at cancer
diagnosis time. If we introduce a point of tumor initiation, where risk of diagnosis
and metastasis are zero, we would need even stronger assumptions than the current
model.
While we denote these stages as unique, the demarcation of these stages is not
always clear. Such is the case with metastasis in our SEER example. Treatments
taken from the time-of-diagnosis, while not affecting time-to-metastasis in patients
whose cancer had already metastasized prior to diagnosis, should have affect time-
to-metastasis in the rest of patients. This ability to select different covariates for
each stage, and at the same time allow latter stages to be dependent upon earlier
stages, may reveal the effect of treatment at different stages and help guide clinical
decision making.
The optional pathways in the joint likelihood further makes our proposed model
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adapatable to describe different disease processes. In some cancers, death occurs
after metastasis. In others, death may occur at any point after diagnosis. To model
the latter, an additional term to the likelihood can reflect the possibility of a patient
dying without intermediate stages, while the estimation procedure remains the same.
This can also be generalized to model different segments of the diseases, such as the
time between recurrence and death.
In this paper treatment is a choice that the physician makes at diagnosis, based
on the observed information at that point, under the assumption of no unmeasured
confounding. It is common to consider treatment as a fixed (external) covariate for
the post-diagnosis model in this context. In reality though treatment represents a
label for what essentially is a dynamic treatment regimen that will follow diagnosis.
One potential problem is that this future information depends on internal processes in
the subject that are unmeasured in registry data, and are not included in the current
model. Another problem is that the assumption of no unmeasured confounding is
likely unrealistic, and treatment decisions at diagnosis occur in part based on some
unmeasured clinical information. All this calls for caution interpreting treatment
effects in this paper as they absorb these effects.
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CHAPTER III
Shared Frailty in Joint Model of Cancer Incidence and
Mortality
3.1 Introduction
It is common for diseases to progress through multiple events between clinical
onset and death. In the context of cancer studies, the age at which a patient is di-
agnosed with cancer can also be described as the time-to-diagnosis. After diagnosis,
there may be other events of interest such as remission, recurrence, and death. Usu-
ally these events are analyzed independently using the time-to-event as an outcome.
However, the relationship between the events driven by the same disease calls for a
joint analysis.
In this paper, we focus on the time-to-diagnosis and the time-to-death. Most
existing methods use time-between-diagnosis-and-death as the outcome of interest to
draw inference about treatment effect. This circumvents the need to look at the two
different outcomes, but assumes that there is no difference in post-diagnosis survival
conditioning on diagnosis time. This assumption is not valid for many diseases.
Intuitively, one may expect patients who are diagnosed at younger ages to survive
longer compared to those who are diagnosed at older ages. Yet, positive correlation
between diagnosis time and post diagnosis survival time have been observed in some
diseases. For example, consider the motivating setting of SEER breast cancer data.
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It has been shown that younger breast cancer patients have worse survival compared
to women diagnosed at an older age Tsodikov (2002). The speculation was that
more aggressive cancers grow faster causing them to surface earlier and have shorter
survival. As we will show (section 3.5), even models that include diagnosis age as
a covariate for risk of death is inadequate to capture this correlation. Thus, we
advocate for joint modeling time-to-diagnosis (and potentially other intermediate
events) and time-to-death using frailties to explain the correlation induced by the
shared disease process.
Existing models often do not adequately capture the relationship between vari-
ous stages in the natural progression of some diseases. Semi-competing risks (Fine
et al., 2001) can model events in which one occurrence prevents the other from being
observed, but cannot model events that occur sequentially. The illness-death model
(Andersen and Keiding, 2002) was introduced as the simplest variation of a multi-
stage model (Andersen et al., 1991; Xu et al., 2010; Kalbfleisch and Prentice, 2011;
Hougaard and Hougaard, 2000). This models the probabilities of moving between
any two specific stages, but it is not able to describe how the time spent in one stage
might affect time spent between other stages (e.g. breast cancer patients diagnosed
at younger ages tend to have shorter post-diagnosis survival time). Recent works in
joint modeling proposed a semiparametric joint likelihood approach with a common
baseline hazard for time to two different events (Hu and Tsodikov, 2014a; Rice and
Tsodikov, 2016). This model, however, is also unable to predict the positive cor-
relation between diagnosis time and post-diagnosis survival as illustrated in breast
cancer patients described in Tsodikov (2002).
Our model incorporates two nonparametrically specified baseline hazards for diag-
nosis and death. We found in analyzing SEER data that there is a level of dependence
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between disease stages that could not be accounted for by using common covariates
and indicators. Therefore, we have included a frailty term as a latent factor that
correlates time-to-diagnosis and post-diagnosis survival time. The shared-frailty ap-
proach is discussed in Hougaard and Hougaard (2000), Klein (1992), Andersen et al.
(1997), and Zeng et al. (2009). The expectation of the joint likelihood with respect
to this latent frailty term is evaluated via Laplace transforms (Hougaard, 1986).
From this averaged joint likelihood, we are able to derive a nonparametric maximum
likelihood (NPMLE) estimating procedure to estimate unique baseline hazards for
diagnosis and death, treatment effects, and the variance of the frailty term. We
derive a closed form expression for post-diagnosis survival prediction and capture
survival dependence on the diagnosis time.
Figure 3.1 shows a typical cancer’s progression as recorded in the National Cancer
Institutes Surveillance Epidemiology and End Results (SEER) registry. To analyze
such data, we use population counts that include healthy individuals to account for
those at risk of a breast cancer diagnosis from birth. Once diagnosed with cancer,
we use individual level data to access risk of death due to breast cancer. Patients




Figure 3.1: Diagram of cancer progression: Patients are diagnosed with cancer at time Tdx and die
at time Td. Tpost−diagnosis indicates the survival time after diagnosis.
In section 3.2, we provide notation and the model description (3.2.1), data struc-
ture (3.2.2), counting processes (3.2.3), joint likelihood (3.2.4), score functions and
estimating procedure (3.2.5), and asymptotic properties (3.2.6). In Section 3.3, we
use Monte Carlo simulations to verify the model’s perfomance and its robustness
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against dependent censoring. In section 3.4, we present our model fit for breast
cancer using SEER data to demonstrate its interpretation, closed form prediction
functions, and its ability to handle latent correlation in multi-stage time-to-event
data. In section 3.5, we show that the model where diagnosis age is used as covariate




Let T ∗1 and T
∗
2 be the potentially observable times of diagnosis and death, respec-
tively; Z be the set of covariates, which consists of Z1 - covariates that are available
at time 0 (e.g. race, gender, etc.) and Z2 - additional covariates after diagnosis
(e.g. treatments); and A be the common frailty term among all disease stages. De-
note hdx(t) and hd(t) as the baseline hazards of diagnosis and death, respectively, to
be estimated non-parametrically; and 1(·) as an indicator function. We define the
following conditional hazards:
• Time-to-diagnosis: λdx(t | A,Z1) = Ahdx(t)θ(Z1),
• Time-to-death: λd(t | Tdx, A,Z) = Ahd(t)γ(Z)1(t ≥ Tdx),
where θ(Z1) = e
βTθ Z1 , γ(Z) = eβ
T
γ Z , and A ∼ Gamma( 1
φ(Z1)
, φ(Z1)), where φ(Z1) =
eβ
T
φZ1 . The advantage of this type of frailty is that we can eventually average (i.e.
find the expectation) with respect to this latent term using a Laplace transform.
Let β = [βθ, βγ, βφ] be the coefficient vector that we would like to estimate. Denote
S?(t) and f?(t) as the corresponding survival and density functions, respectively, for
hazard functions λ?(t).
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3.2.2 Observed Data Structure
Let V ? be the censoring time, independent of (T ?1 , T
?
2 ) given Z; and ξ be the
maximum follow-up time of the study. For each subject i = 1, 2, ..., n in the study,
we observe {T1i, T2i, ∆1i, ∆2i, Zi}, where T1i = min(T ∗1i, V ?i , ξ) is the time to the first




i , ξ) is the time to the second
event (i.e. death or censoring); ∆1i = 1(T1i = T
?
1i) is an indicator of observing
diagnosis; ∆2i = 1(T2i = T
?
2i)∆1i is an indicator of observing death after diagnosis.
3.2.3 Combine population risk-set and cancer events
Let Y1i(t) = 1(t ≤ T ?1i) and N1i(t) = 1(T ∗1i < t) denote subject i’s risk process and
counting process, respectively, for a cancer diagnosis. Let Y2i(t) = 1(T1i < t < T2i)
and N2i(t) = 1(T
∗
2i < t)N1i(t) denote the risk process and counting process for death
due to cancer.
SEER case data only include subjects who are diagnosed with cancer. This is
sufficient if we are only interested in estimating the risk of death in such subjects.
However, we are also interested in estimating the risk of being diagnosed with cancer
in the general population. Thus, we need to invoke a separate dataset that tracks the
size of the at-risk population from which our cancer cases originate. This separate
dataset essentially provides cross-sectional life-table data for cancer diagnosis, and
the SEER data includes subject-level follow-up for cancer death.
Figure 3.2 outlines how we use population counts as the risk set for diagnosis
events. Since our breast cancer diagnoses are from females in Michigan between
1973-2011, we use counts of the female population during the same time period and
in the same geographic location, stratified by Z1, to define the risk-set for breast
cancer diagnosis. Let Yz1(t) denote the population counts for the subset that takes
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value z1 for covariate set Z1. Instead of summing up n cancer subjects, we sum



















Figure 3.2: Using population counts as risk set for diagnosis events. Z1 = race; Ywhite(t), Yblack(t),
and Yother(t) are population counts by race at age t; dN1i(t) denotes breast cancer
diagnosis for subject i from the population; Y2i(t) denotes subject i being at risk of
death due to breast cancer; dN2i(t) is the recorded death.
3.2.4 Likelihood Construction
For ease of notation, denote fdxfd(t1, t2) as the joint probability of the sequence
of diagnosis at t1 followed by death at t2. Dropping subscript i, we can derive the
probability of observing each of the following sequences of events (see Appendix B.1
for derivation):
(1) Subject is diagnosed at t1:
L1(t1) = EA [fdx(t1 | A)] = −hdx(t1)θL(1)Hdx(t1)θ
(2) Subject is censored at t1 before any event is observed:
L2(t1) = EA [SdxSd(t1, t1 | A)] = L(0)Hdx(t1)θ.
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(3) Subject is diagnosed at t1, then dies at t2:
L3(t1, t2) = EA [fdxfd(t1, t2 | A)] = hdx(t1)hd(t2)θγL(2)Hdx(t1)θ+Hd(t2)γ−Hd(t1)γ.
(4) Subject is diagnosed at t1 and is censored at t2:
L4(t1, t2) = EA [fdxSd(t1, t2 | A)] = −hdx(t1)θL(1)Hdx(t1)θ+Hd(t2)γ−Hd(t1)γ.
where L
(k)
s is the kth derivative of the Laplace transform of A with respect to
s. For A ∼ Gamma( 1
φ
, φ), the first three Laplace transformations are as follow:
L
(0)



















log {Θ1i [Hdx(t),Z1] dHdx(t)} dN1i(t)
− Y1i(t)Θ1i [Hdx(t),Z1] dHdx(t)
+ log {Θ2i [Hdx(t1i), Hd(t),Z] dHd(t)} dN2i(t)
− Y2i(t)Θ2i [Hdx(t1i), Hd(t),Z] dHd(t) (3.1)
It is easy to recognize that eq.(3.1) follows the usual counting process notation
for a time-to-event likelihood, but terms are repeated to accomodate both time-
to-diagnosis and time-to-death. For ease of notation in the rest of this paper, we
shorten Θ1 [Hdx(t),Z1] and Θ2 [Hdx(t1), Hd(t),Z] to Θ1(t) and Θ2(t; t1), respectively.
Θ1(t)dHdx(t) is the hazard of diagnosis at time t and Θ2(t; t1)dHd(t) is the hazard of
death due to cancer at t after diagnosis at t1. These quantities can be derived (see




















As discussed in section 3.2.3, we use a separate population count dataset to obtain
the number of people at risk for the event of diagnosis. Because we use Z1 =race as
a covariate for the risk of cancer diagnosis, we stratify the population count by Z1
(this stratification is available in SEER using race as a covariate) and substitute the
at-risk count Y1i(t) by Yz1(t) and the event count N1i(t) by Nz1(t), where Z1i = z1.











log [Θ2i(t; t1)dHd(t)] dN2i(t)− Y2i(t)Θ2i(t; t1)dHd(t).
(3.4)
3.2.5 Nonparametric maximum likelihood estimator (NPMLE)
Score Functions
We use a profile likelihood approach to perform NPMLE with respect to Hdx(t),



















tional derivatives with respect to dH follow the intuition of differentiating over jumps
of a step-function in the discrete case, and are rigorously defined in Hu and Tsodikov
(2014a,b) to be valid for continuous functions as well.



































where martingales (at the true model) dM(t) are defined as follows:
dMz1(u) =dNz1(u)− Yz1(u)Θz1(t)dHdx(t), ∀z1 values of Z1
dM2i(u) =dN2i(u)− Y2i(u)Θ2i(t; t1i)dHd(t).
Estimation Procedure
Given β, we derive Breslow-type estimators for Hdx(t) and Hd(t) by solving the
score functions given in equations 3.5 and 3.6. The jump in baseline hazards d̂Hdx














Y2i(x)ω2i(Hd, Hdx, x)Θ2i(x; t1i)
, (3.9)




. Here we use H to denote the full trajectory of
the function H as opposed to a single value of the function.
Denote t = {t(1), t(2), ..., ξ} as the set of unique times, with ξ the last time point,
where events occur in the data. Simultaneous maximization of the log-likelihood
with respect to Hdx, Hd, and β is done using a profile likelihood approach and an
iterative reweighting algorithm (Chen, 2009) as follows:
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1. For a candidate β?, start with weight ω(0)(t) = 1 and d̂H
(0)
dx (t) = Nelson-Aalen
estimator.
2. Repeat until convergence of ̂dHdx(t):
- Use d̂H
(0)
dx (x) to calculate Θ
(0)




(0) = 1, and eq.3.8 to calculate d̂H
(1)
dx (x). With the weight
fixed, the right hand side of eq.3.8 only depends on prior jumps Hdx(t),
∀t < x.
- Sequentially calculate the jump size in baseline hazard along all time x ∈ t
to get the full path Ĥ
(1)
dx .
- Use full path Ĥ
(1)
dx to update weights ω
(1).
3. Use converged Ĥdx and a similar process as in the previous step to find Ĥd .
4. Calculate the profile log-likelihood `pr(β
?, Ĥdx, Ĥd) using eq.3.4.
5. Repeat steps (1-4) to search for β̂ = arg max
β
`(β).
Standard errors are estimated using the Hessian of the profile log-likelihood (see
Appendix B.4 for outline of proof).
3.2.6 Asymptotic properties














































which are martingales under the true model (see Appendix B.3).
Consistency and weak convergence Consistency and weak convergence result
of the NPMLE Ω̂ = (β̂, Ĥdx(t), Ĥd(t)) is adapted from Rice and Tsodikov (2016).
Assuming regularity conditions hold,
(i) With probability one, β̂ converges to β0, Ĥdx converges to H
0
dx, and Ĥd converges





0 are the true values of
Hdx, Hd, β.
(ii) n1/2{β̂ − β0, Ĥdx(t) − H0dx(t), Ĥd(t) − H0d(t)} converges weakly to a zero-mean
Gaussian process. In addition, nET (In)−1E converges in probability to the




aT (β̂ − β0) + b(t)T (Ĥdx(t)−H0dx(t)) + c(t)T (Ĥd(t)−H0d(t))
}
, where a
is real vector, b(t) and c(t) are functions with bounded total variation in [0; ξ],
ET = (aT , BT ) where B is a vector of the values of b at the jumps of Ĥ, and
In is the negative Hessian matrix of the observed log-likelihood function with
respect to Ω̂.
3.3 Simulation Studies
We performed Monte Carlo simulations to assess the proposed methodology. For
each scenario, 1000 sample replicates with sample sizes 500 and 1000 were performed.
The parameters were set as follow: Frailty term A ∼ Gamma with mean 1 and vari-
ance eβ
T
φZ1 where βφ = [−1, 0.4, 0.7]; covariates Z1 ∼ Binom(3, 0.5), Z2 ∼ N(2, 0.5),
and Z3 ∼ Bern(0.5); increasing baseline hazard Hdx ∼Weibull(5, 10) and decreasing
Hd ∼ Weibull(0.5, 4). Time-to-diagnosis and time-to-death were generated under
Cox proportional hazards using βθ = [1.6, 0.5], and βγ = [2,−0.7, 1.4]. Independent
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censoring time followed a uniform distribution U(8, 15), which yielded approximately
25% censoring before diagnosis and 50% censoring before death.
Table 3.1: Simulation results
Diagnosis Death Frailty
N Statistics βθ βγ βφ
True 1.6 0.5 2 -0.7 1.4 -1 0.4 0.7
500 Bias 0.02 0.01 0.05 -0.02 0.03 -0.05 -0.002 -0.01
SD(β̂) 0.26 0.40 0.36 0.39 0.35 0.58 0.36 0.39
Avg(ŜE) 0.19 0.24 0.23 0.25 0.20 1.52 1.14 0.41
95% CP 94.5 93.9 92.0 94.1 94.3 93.3 94.8 94.2
1000 Bias 0.01 -0.004 0.03 -0.02 0.02 0.01 -0.003 0.001
SD(β̂) 0.14 0.18 0.17 0.18 0.13 0.34 0.07 0.11
Avg(ŜE) 0.13 0.17 0.16 0.17 0.14 0.32 0.08 0.11
95% CP 95.3 93.5 93.5 93.8 94.8 93.4 95.3 94.9
SD(β̂): Empirical standard deviation of estimated β̂ coefficients
Avg(ŜE): Average of 1000 estimated standard errors (using Hessian matrix)
95% CP: 95% coverage probability.
The simulation results are summarized in Table 3.1. The estimated log-hazard-
ratio (LHR) for time-to-diagnosis and time-to-death are very close to the true β
and the bias decreases as sample size increases. The empirical standard deviation of
1000 Monte Carlo replicates are similar to the average of estimated standard error,
validating our estimation of standard error. The differences decrease further with
large sample size n=1000.
The estimation for parameter of frailty term A (βφ) also performed well. The
biases were small at sample size n=500, and get smaller with larger sample size.
There is a discrepancy in the standard error estimation (difference between SD(β̂)
and Avg(ŜE) at smaller sample sizes, but it vanished for sample sizes as large as
1000. The performance of our proposed model is robust when switching between
increasing and decreasing baseline hazards for hdx(t), hd(t), and different values of
βφ (results not shown).
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3.4 Application to SEER breast cancer data
3.4.1 Data
We applied our proposed model to the motivating setting of SEER breast cancer
data. We use Michigan data because the Michigan population is sufficiently diverse,
allowing us to include race as a covariate in the model.
SEER cancer case: The SEER-18 database provided information on race, age
at diagnosis, and the survival time of women who were diagnosed with breast cancer
between 1973-2011. Out of all recorded cases in this time period, we concentrated
on women between the ages of 20-84. Subjects with unknown race, age, or treatment
were removed under the assumption of missing at random. Deaths from other causes
and those alive at the end of data collection period were censored. The breakdown of
data collected and used for analysis by race and treatment is summarized in Figure
3.3.
SEER population data: We used a separate SEER dataset to obtain counts of
the female population by race in Michigan for each age between 20 and 84. These
numbers were summed across the span of years recorded in the data (1973-2011) to
define the at-risk set for each age. Modification to the log-likelihood to incorporate
this new risk-set is shown in eq.(3.4).
3.4.2 Results
Figure 3.4 shows our estimated baseline cummulative hazards for diagnosis and
death from SEER breast cancer data. The baseline hazard of diagnosis is on a smaller
magnitude (left y-axis) compared to that of death because the population at risk of
cancer diagnosis (i.e. Michigan female population) is much bigger than that of death
(i.e. Michigan breast cancer patients). More importantly, we note that the shapes
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Figure 3.3: SEER population and breast cancer case data (Michigan, 1973-2011) using in our anal-
ysis. # denotes number, n denotes number of observations.
Population data: #females from Michigan
aggregated between 1973-2011. Stratified
-By age (20, 21, ..., 84)
















of these two baseline hazards are substantially different and would not satisfied the
common baseline hazard assumption from Hu and Tsodikov (2014a,b). Additionally,
most parametric transformations could not adequately relate one baseline hazard to
the other, thus strenthening the use of our model.
Table 3.2 shows the estimated covariate effects on time-to-diagnosis and time-to-
death, respectively. The coefficients in table (a) and (b) denote log-hazard ratios
with respect to the reference group (white women). A positive coefficient signifies
higher risk and thus a faster time-to-event.
White women were found to have slightly lower risk of breast cancer diagnosis
compared to black women (β̂θBlack = 0.56, P < 0.001). There was not significant
evidence of a difference compared to women of other races (β̂θOther = 0.11, P = 0.21).
Once diagnosed with breast cancer, race was also found to be an important factor
affecting survival time. Black women had a slightly lower risk of death due to cancer
(i.e. survive longer) compared to same-age white women (β̂γBlack = −0.64, P <
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Figure 3.4: The shapes of baseline cummulative hazards for diagnosis events and death events
in the SEER breast cancer data are too distinct to get from one to the other using
transformation.
0.001). Women from other races had the lowest risk relative to black and white
patients (β̂γOther = −3.12, P < 0.001).
Table 3.2: SEER breast cancer analysis
(a) LHR for time-to-diagnosis (βθ)
Covariate Estimate SE P-value
ZBlack 0.56 0.02 <.001
ZOther 0.11 0.09 0.21
(b) LHR for time-to-death (βγ)
Covariate Estimate SE P-value
ZBlack -0.64 0.07 <.001
ZOther -3.12 0.15 <.001
ZSurgery -2.61 0.05 <.001
ZRadiotherapy -0.04 0.09 0.67
ZCombination -2.73 0.05 <.001
(c) Gamma frailty parameters (βφ)
Covariate Estimate SE P-value
ZWhite 1.61 0.10 <.001
ZBlack 3.10 0.05 <.001
ZOther 5.16 0.08 <.001
LHR: Log-hazard ratio versus reference group
(white women who received no treatment).
SE: Estimated standard errors.
Treatment options that involved surgery (mastectomy) were found to improve sur-
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vival time compared to no immediate treatment. Specifically, surgery in combination
with radiotherapy was most effective (β̂γCombo = −2.73, P < 0.001) and marginally
better than surgery by itself (β̂γSurgery = −2.61, P < 0.001). There was not enough
evidence for the effectiveness of radiotherapy alone (β̂γRadiotherapy = −0.04, P = 0.67).
The latent correlation between time-to-diagnosis and time-to-death previously
unaccounted for was detected in our proposed model. The common frailty term in
the hazards for diagnosis and death followed a Gamma distribution with mean 1
and variance e1.61 in white patients, e3.10 in black patients, and e5.16 in patients from
other races. The effect of this frailty term is more apparent when we explore the
correlation between time-to-diagnosis and time-to-death (Figure 3.6).
3.4.3 Predicted Survival Rates and Diagnosis Plots
One of the advantages of our proposed model is that there are closed form ex-
pressions for the survival functions of the time-to-each-event (or between events) of
interest.
Figure 3.5 shows the empirical Kaplan-Meier curves for the diagnosis of breast
cancer among different racial groups in Michigan. The predicted rates from our
proposed model, as given by equation 3.13, are very similar to the empirical rates
for all racial groups.
Sdx(t|Z) = L3(t) = L(0)Hdx(t)θ (3.13)
We also plotted the post-diagnosis survival time conditioned on age at diagnosis
(eq.3.14) in Figure 3.6.











Our model is able to predict the adverse effect of age at diagnosis on survival time
without explictly using diagnosis-age as a covariate in an overall survival model. For
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Figure 3.5: Percentage of women without a breast cancer diagnosis in the Michigan population for
each racial group from 1973-2011. Proposed model predictions Ŝ1(t1|Z) (dotted lines)
from eq. (3.13) are compared to empirical Kaplan-Meier estimates (solid lines).
example, patients diagnosed at 35 years old have worse survival compared to those
diagnosed at 50 (or 70) years old after the same time period from diagnosis. This
adverse age effect diminishes in older groups. Those diagnosed at 50 have slightly
worse prognosis compared to 70 year-old patients. Figure 3.6 includes only the subset
of white women who received surgery post diagnosis, but results for other treatment
options and racial groups were similar (not shown).
3.5 SEER Analysis: Reset clock to 0 at diagnosis time
We also tried the following 2 models where time-to-death is reset to 0 at diagnosis
time (Tdx). Denote s as the time-since-diagnosis.
M1: λd(s | Tdx, A,Z) = Ahd(s)eβTγ Z
M2: λd(s | Tdx, A,Z) = Ahd(s)eβTγ Z+β21(20≤Tdx≤40)+β11(40<Tdx≤60)+β31(Tdx>60)
Table 3.3 shows the log-hazard ratios from 2 models where time-to-death was reset
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Figure 3.6: Women diagnosed at a younger age have worse survival post diagnosis. This plot shows
post-diagnosis survival among white women who received surgery. We focus on those
that were diagnosed at younger age (35 years old) versus older age (50 or 70 years old).
The prediction from our proposed model ŜTd−Tdx(t | tdx) (dash lines) from eq. (3.13)
are plotted against the empirical Kaplan-Meier curve (solid lines).
































M2 prediction for post−diagnosis survival
 among white females who received surgery 
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Figure 3.7: Predicted curves for post-diagnosis survival ŜTd−Tdx(t | tdx) among white women who
received surgery using model M1 (left plot, dash lines) and model M2 (right plot, dash
lines) are plotted against the empirical Kaplan-Meier curve (solid lines).
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(a) Log hazard ratios for time-to-diagnosis (βθ) and SE
Covariate Proposed M1 M2
ZBlack 0.56 (0.02) 0.61 (0.02) 0.60 (0.02)
ZOther 0.11 (0.09) 0.15 (0.09) 0.13 (0.09)
(b) Log hazard ratios for time-to-death (βγ) and SE
Covariate Proposed M1 M2
ZBlack -0.64 (0.07) -0.35 (0.11) -0.67 (0.17)
ZOther -3.12 (0.15) -2.64 (0.17) -3.04 (0.23)
ZSurgery -2.61 (0.05) -2.52 (0.05) -2.49 (0.06)
ZRadiotherapy -0.04 (0.09) -0.02 (0.09) -0.02 (0.09)
ZCombination -2.73 (0.05) -2.68 (0.06) -2.66 (0.06)
1(40 < Tdx ≤ 60) - - -0.20 (0.03)
1(Tdx > 60) - - -0.21 (0.04)
(c) Gamma frailty parameters (βφ) and SE
Covariate Proposed M1 M2
ZWhite 1.61 (0.10) 2.14 (0.16) 1.67 (0.25)
ZBlack 3.10 (0.05) 3.33 (0.05) 3.22 (0.06)
ZOther 5.16 (0.08) 5.23 (0.07) 5.18 (0.08)
Table 3.3: Comparing proposed model to M1 and M2 using SEER breast cancer analysis. (LHR:
Log-hazard ratio versus reference group (white women who received no treatment). SE:
Estimated standard errors.)
to 0 at diagnosis. This is possible because we estimate the baseline hazard for diag-
nosis and death separately. The estimated log-hazard-ratios are consistent with our
proposed model where we did not reset the clock. However, this new model requires
explicit inclusion of diagnosis age as covariates for risk-of-death. This necessitates
deciding whether to treat diagnosis age as continuous covariates or adding splines.
Even with the later approach, the model’s prediction for overall survival time, con-
ditioned on diagnosis time, does not fit as well as our proposed model where we did
not have to include age or diagnosis time as a covariate.
3.6 Discussion
The effects of demographic factors and therapeutic interventions on the overall
survival time of patients in any disease is not a new problem in survival analysis.
Common methods of analysis include Cox proportional hazards and frailty models.
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Situations where a certain event (e.g. death due to a particular cause) prevents others
from being observed (e.g. death from other causes) have been studied extensively
within the competing risks framework. However, there is no agreed-upon procedure
to model cancer data where there are multiple stages (i.e. diagnosis, metastasis,
remission, relapse, and death) of interest that make up the entire disease natural
history. Intuitively, the stages of interest have the same underlying biological cause
and thus their time-to-events should be analyzed simultaneously.
The current common practice fails to take into account the relationship between
stages. Due to its convenient availability, Cox models are often used to analyze time-
to-stages as independent outcomes. Less naive approaches using competing-risks or
semi-competing-risks model only stages that directly compete with each other and
ignore their relationships with other stages that come earlier or later. The non-
identifiability issue in competing-risks prevents full estimation of the non-parametric
baseline hazard.
Instead of using the same baseline hazard for all stages to construct the joint
likelihood, we extended the joint modeling approach to estimates a baseline hazard
for the first observed event (i.e. diagnosis) and a different baseline hazard for the
next event (i.e. death) conditioning on the former. In practical terms, this assump-
tion would increase computing time due to having to estimate two baseline hazards
non-parametrically. But the advantage is that it relaxes the restriction and captures
the full dependence between stages. Earlier versions of our model that estimate one
baseline hazard non-parametrically and use a parametric transformation (e.g. raise
the estimated cummulative baseline hazard to a power) to arrive at the second base-
line hazard were also not flexible enough to predict the positive correlation between
diagnosis time and post-diagnosis survival.
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Our proposed model can easily be generalized to include more cancer stages such
as metastasis, remission, or recurrence. We can estimate unique baseline hazards
for each of these stages as long as the onset times are observed. In the case where
a stage is not observed (e.g. positive metastasis status at diagnosis time indicates
metastasis onset at unknown time prior to diagnosis) preventing the non-parametric
estimation of its baseline hazard, we can arrive at its estimate using a parametric
transfomation of the baseline hazard from another observed stage. We found this to
be a good approach to model diagnosis, interval-censored metastasis, and death in
prostate cancer. This, of course, requires making the assumption that the unobserved
stage and observed stage have a similar enough underlying disease process that can
be modeled via a transformation.
Future research in this area includes modeling recurring stages and partial miss-
ingness. More development to speed up the estimation procedure would also help
make this joint modeling approach more attractive to researchers.
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CHAPTER IV
Joint Modeling and Multiple Comparisons with the Best of
Data from a SMART with Survival Outcomes
4.1 Introduction
Many diseases, chronic and acute, require ongoing treatment. Multiple first- and
second-line treatment options are available for many diseases, but most evidence for
optimal treatment focuses on one specific time point. The best treatment strategy
over the course of the disease, however, may include sequences of treatments that de-
pend on previous treatments. A dynamic treatment regimen (DTR) (Murphy et al.,
2001) is a guideline providing first-line and second-line treatment, where second-line
treatment is specified based on response to first-line treatment. For diseases and
disorders where DTRs are standard practice, evidence for optimal clinical decision
rules considering more than one stage of treatment is necessary. A sequential multi-
ple assigment randomized trial (SMART) (Murphy, 2005; Lavori et al., 2000; Lavori
and Dawson, 2004) is one such type of trial design that can assess entire treatment
regimens and build effective DTRs. In such a multi-stage trial, second-line treatment
may be randomized based on a patient’s outcome to a first-line treatment. DTRs are
embedded within a SMART for estimation and comparsion. The goal of a SMART
is to identify decision rules or DTRs that result in the best overall outcome.
Figure 4.1 shows three common SMART designs. In design I, there are 8 em-
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bedded DTRs: {A1B1C1}, {A1B1C2}, {A1B2C1}, {A1B2C2}, {A2B1C1}, {A2B1C2},
{A2B2C1}, and {A2B2C2}, where each set consists of first stage treatment (A1 or
A2), second stage treatment for responders (B1 or B2), and second stage treatment
for non-responders (C1 or C2). Note that every person is consistent with two DTRs
(e.g. A1B1 group is part of both regimens {A1B1C1} and {A1B1C2}; A1C1 group
is consistent with {A1B1C1} and {A1B2C1}, etc.) This feature of a SMART allows
for efficient use of each subject’s information to estimate the regimen outcome (Ko
and Wahed, 2012). Design II shows a variation of a SMART design where second-
line treatments are only assigned to responders resulting in 4 DTRs: {A1B1C1},
{A1B2C1}, {A2B1C1}, and {A2B2C1}. Design III has second-line treatments only
for responders from A1, resulting in 3 DTRs {A1B1C1}, {A1B2C1} and {A2B1C1}.
Note that “response” and “non-response” may switch in different context, but this
change is trivial. Further, many other possible SMART designs exist with different
number of stages and treatments.
Many published methods for the analysis of data from a SMART consider con-
tinuous outcomes. This is due to the ease of model parameterization and robust
theoretical properties (Murphy, 2005; Oetting et al., 2011; Orellana et al., 2010).
Since many DTRs can be embedded within a SMART, multiple comparisons can be
an issue. The issue of multiple DTR comparisons has been addressed for contin-
uous outcomes using Ertefaie et al. (2016), but it is an open probelm for survival
outcomes.
Survival outcomes have been assessed in SMART literature. Many estimators
have been built upon the inversed probability weighting (IPW) framework: Lunce-
ford et al. (2002) used IPW to average responders and non-responders in each regi-


















































Figure 4.1: Three common two-stage SMART designs. R is first randomization to first-line tre-
tament A1 (X = 0) or A2 (X = 1). ∆
r and ∆nr are indicators of responders and
non-responders to first-line treatment, respectively. B1 (Z
r = 0) and B2 (Z
r = 1)
are second-line treatment options for responders. C1 (Z
nr = 0) and C2 (Z
nr = 1)
are second-line treatment options for non-responders. Pj = P (Z
r = 1 | Aj) and
Qj = P (Z
nr = 1 | Aj) are second-line randomization probabilities after treatment Aj ,
j = 1, 2. In design I, both responders and non-responders are re-randomized to sec-
ond treatment. In design II, only responders are re-randomized. In design III, only
responders from A1 are re-randomized.
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combined time-dependent IPW and Nelson-Aalen estimators to estimate regimens’
survival rates; Feng and Wahed (2008) proposed a modified supremum weighted
log-rank test and Miyahara and Wahed (2010) introduced a weighted Kaplan-Meier
estimator. Wahed (2010) used a mixture of exponential, normal, and Weibull dis-
tributions to model survival times from different regimens. Some of these works
were followed up with large sample properties and sample-size formulae including
methods by Feng and Wahed (2009) and Li and Murphy (2011). Even though these
methods estimate the averaged survival outcomes of DTRs (e.g. mean survival time
or survival probabilities), none of them offer a way to parameterize treatment effects,
interactions, and incorporate auxiliary variables beside treatment assignment.
Methods that do incorporate auxiliary variables extend the standard Cox model.
Lokhnygina and Helterbrand (2007) incorporated IPW into a Cox model to compare
separate-path DTRs (e.g. independent DTRs with different first-line treatment such
as A1B1C1 and A2B1C1 in design II), but could not compare shared-path DTRs
(Kidwell and Wahed (2013), e.g. DTRs with overlapping patients such as A1B1C1
and A1B2C1 in design II). Thall et al. (2007) proposed a Bayesian joint model that
regressed the overall survival time on intermediate response time, but assume a
rather restrictive Weibull distribution for both time points. Recently, Tang and
Wahed (2015) assigned different Cox baseline hazards for each DTR and modeled
auxiliary variables as covariates effects on the hazard ratios. This approach used
different baseline hazards to represent the overall difference between DTRs but did
not offer a way to measure each treatment’s effect and their interaction within DTRs.
Moreover, Tang and Wahed (2015) assumed that the auxiliary covariates’ effects were
constant over different treatment stages within each DTR and across different DTRs.
In this manuscript, we propose a joint modeling approach that consider the at
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time-to-response and time-to-death together. The joint model offers a way to mea-
sure first- and second-line treatments within a regimen and their interactions while
naturally adjusting for SMART randomization probabilities. Unless otherwise stated,
the notation and simulation results are based on design II. As we will show, adap-
tations for designs I and III are straightforward. In section 4.2.1, we introduce the
notation for a SMART setting with a survival outcome. In section 4.2.2, we introduce
our joint model, the resulting joint log-likehood (section 4.2.3), and estimation pro-
cedure (section 4.2.4). We illustrate the estimation performance using Monte Carlo
simulations (section 4.3.1). We briefly discuss previously proposed non-parametric
survival estimators and compare them against our model’s predictive performance
(section 4.3.2). Finally, we implement multiple comparisons with the best (MCB) to
compare survival rates at some time t between DTRs (section 4.4) and provide some
discussion (section 4.5).
4.2 Joint model and NPMLE
4.2.1 Notation for SMARTs data structure
Assume a SMART design with two intervention options for first- and second-line
treatment for responders, and 1 option for second-line non-responders (Design II,
Figure 4.1). We use the counterfactural framework to summarize the set of covariates
and potential outcomes from each subject i:
{Vi, Xi, Zri , Znri , T ri , T di , T ci ,∆ri ,∆nri ,∆di }
where V is the set of baseline covariates, X is an indicator of first-line treatment
(X = 0 for A1, X = 1 for A2), Z
r is an indicator of second-line treatment for
responders (Zr = 0 for B1, Z
r = 1 for B2), Z
nr is an indicator of second-line
treatment for non-responders (Znr = 0 for C1). We define non-responders as those
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who have not responded by a cut-off time tnr. Denote Pj = P (Z
r = 1 | Aj) and
Qj = P (Z
nr = 1 | Aj) = 0 as the second-line randomization probabilities among
responders and non-responders, respectively. These notations can be generalized for
design I and III.
T r, T d, and T c are potentially observed time-to-response, time-to-death, and
censoring time, respectively. If a patient does not respond by tnr or dies first,
T r is not observed. Thus, we can relate the first observed event time as T1 =
min(T r, tnr, T d, T c). Indicators ∆r = 1(T r = T1) and ∆
nr = 1(tnr = T1) de-
note whether the patient is a responder or non-responder, respectively. Note that
∆r + ∆nr = 0 indicates that a patient was censored or died before response assess-
ment.
If ∆r + ∆nr = 1, a patient is re-randomized to receive a second-line treatment.
Subsequent survival time or censoring time is observed at T2 = min(T
d, T c). Indica-
tor ∆d = 1(T d = T2) denotes that a death is observed.
4.2.2 Model
We introduce conditional hazards to model time-to-response and time-to-death.
Denote hr(t) and hd(t) as the non-parametric baseline hazards (Hr(t) and Hr(t)
are the cummulative hazards) of response and death, respectively, and 1(·) as an
indicator function. Then, we define the following:
• time-to-response:
λr(t) = hr(t) exp{β1V + β2X}, (4.1)
• time-to-death:
λd(t) = hd(t) exp {β3V + β4X + ∆r1(t > tr)(β5 + β6X + β7Zr + β8XZr + β9XZrV )
+∆nr1(t > tnr)(β9 + β10X)} . (4.2)
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Note that in design II, all regimens have Znr = 1, thus its effect is absorbed into
the baseline hazard. For ease of notation, we denote θ = eβ1V+β2X , γ = eβ3V+β4X ,
η = γeβ5+β6X+β7Z
r+β8XZr+β9XZrV , and µ = γeβ10+β11X . Denote S(t) and f(t) as the
corresponding survival and density functions, respectively, for hazard functions λ(t).
The current form of eq. (4.2) can easily be adapted for designs I and III as follows.
Design I λd(t) = hd(t) exp {β3V + β4X + ∆r1(t > tr) (β5 + β6X + β7Zr + β8XZr
+β9XZ




Design III λd(t) = hd(t) exp {β3V + β4X + 1(A1)∆r1(t > tr)(β5 + β6Zr + β8XZr)} .
4.2.3 Counting Processes and Likelihood Construction
Denote frfd(t1, t2) as the joint probability of the sequence of response at t1, fol-
lowed by death at t2. With some algebra, the joint log-likelihood can be expressed

















+ log {Θr2i(t | t1)dHd(t)} dN r2i(t)− Y r2i(t)Θr2i(t | t1)dHd(t)
+ log {Θnr2i (t | t1)dHd(t)} dNnr2i (t)− Y nr2i (t)Θnr2i (t | t1)dHd(t), (4.3)
where ξ is the maximum follow-up time, Θr1(t) and Θ
d
1(t) are the hazards of response
(counting process dN r1 (t)) or death (counting process dN
d
1 (t)) first at time t, respec-
tively. Θr2(t | t1) and Θnr2 (t)(t | t1) are the hazards of death after response (counting
process dN r2 (t)) or non-response (counting process dN
nr
2 (t)), respectively. Y1(t) is
the at-risk process for the first event. Y r2 (t) is the at-risk process for death after the
first event is response. Y nr2 (t) is the at-risk process for death after the first event is
non-response.
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It is easy to see that the first three terms in eq. (4.3) of the joint log-likelihood
express the probability of observing the first event (response, non-response, death, or
censoring). The next four terms express the probability of observing the second event
(death or censoring) given the first event was response (subscript r) or non-response
(subscript nr).
The following quantities can be derived (see Appendix C.1 for details):































We derive Breslow-type estimators for Hr(t) and Hd(t) by solving their score
functions. See Supplemental Material Section C.2 for the score functions and a proof
of the martingale properties.
The jump in baseline hazards d̂Hr and d̂Hd at time x are
∂`
∂dHr(x)
















































































, and ωnr2 (x) = 1−
∫ ξ
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using the following martingales
dM r1 (t) = dN
r
1 (t)− Y1(t)Θr1(t)dHr(t) and dMd1 (t) = dNd1 (t)− Y1(t)Θd1(t)dHd(t),
dM r2 (t) = dN
r
2 (t)− Y r2 (t)Θr2(t)dHd(t) and dMnr2 (t) = dNnr2 (t)− Y nr2 (t)Θnr2 (t)dHd(t).
Denote t = {t(1), t(2), ..., ξ} as the set of unique times where events occur in the data.
Simultaneous maximization of the log-likelihood with respect to Hr(t), Hd(t), and
β is done using a profile likelihood approach and an iterative reweighting algorithm
(Chen, 2009) as follows:
1. For a candidate β?, start with weight ω(0)(t) = 1 and Nelson-Aalen estimators
for d̂H
(0)
r (t) and d̂H
(0)
d (t).
2. Repeat until convergence of d̂Hr(t) and d̂Hd(t):
- Use d̂H
(0)
r (x) and d̂H
(0)








2 (x)∀x ∈ t.
- Use Θr1(x), weight ω
r(0)
1 = 1, and eq. (4.4) to calculate d̂H
(1)
r (x) at each
time x ∈ t. With the weight fixed, the right hand side of eq. (4.4) only
depends on prior jumps Hr(t), ∀t < x. Sequentially calculate the jump size
in baseline hazard along all time x ∈ t to get the full path Ĥ(1)r .
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3. Calculate the profile log-likelihood `pr(β
?, Ĥr, Ĥd) using eq. (4.3).
4. Repeat steps (1-3) to search for β̂ = arg max
β
`(β).
Standard errors are estimated using the Hessian of the profile log-likelihood (see
Appendix B.4 for proof of consistency).
4.3 Simulation studies
4.3.1 Performance of estimation procedure
There are many situations where a subgroup of patients react differently to treat-
ment regimens, thus the ability to adjust for auxiliary covariates is crucial to identify
the best regimen. Motivated by this, we designed simulations following SMART de-
sign II where patients with different values of baseline covariates V ∼ Bern(0.75)
had different optimal regimens.
We performed Monte Carlo simulations to assess the proposed methodology in
estimating covariate effects from a SMART with survival outcome. The parameters
were set as follow: n=1000, first treatment randomization probability was P (X =
1) = 0.5. Second treatment randomization probabilities were P1 = 0.5, and P2 = 0.5.
Baseline hazard Hr ∼ Weibull(0.75, 4) and Hd ∼ Weibull(3, 4). Time-to-response
and time-to-death were generated under Cox proportional hazards
• λr(t) = hr(t) exp{β1V + β2X}
• λd(t) = hd(t) exp {β3V + β4X+ ∆r1(t > tr)(β5 + β6X + β7Zr + β8XZr + β9XZrV )}
where β = [−1.5, 0.6,−0.5,−1.3,−1.2,−0.7,−1, 1.8,−2.4].
We chose β to demonstrate the situation where: (i) a particular first-line and
second-line treatment were superior on their own, but their interaction was not as
beneficial overall compared to another combination from less effective single-line
treatments and (ii) subgroups of patients reacted to regimens differently. The for-
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mer justifies the evaluation of DTRs instead of single-line treatment comparisons.
Including the interaction between V and treatment further motivates our model over
existing methods.
In particular, A2 (ie. X = 1) was better than A1: β2 = 0.6 indicated faster time-
to-response and β4 = −1.3 indicated A2 resulted in a lower risk of death overall for
non-responders and in the period pre-response for responders. After response and
second treatment randomization, β7 = −1 indicated B2 (ie. Zr = 1) was better than
B1. However, β8 = 1.8 increased risk and made the combination A2B2 undesirable.
Thus, A2B1C1 was the best regimen for reference subgroup where V = 0. On the
other hand, β9 = −2.4 made A2B2C1 the best regimen for subgroup where V = 1.
The cut-off time for response was set at tnr = 5. Censoring time was generated
from Unif(0, 20), which resulted in 10% censored, 25% death, 50% response and 15%
non-response by time tnr. Of the 65% that received second-line treatment, 25% were
censored before death.
Table 4.1: Simulation for Design II: Estimated log hazard ratios and SE
Response Death first Death after 2nd randomization
N Statistics βθ βγ βη
True -1.5 0.6 -0.5 -1.3 -1.2 -0.7 -1 1.8 -2.4
200 Bias 0.00 0.01 -0.02 -0.01 0.00 -0.07 -0.03 0.10 -1.03
SD(β̂) 0.24 0.24 0.24 0.23 0.36 0.53 0.54 0.80 2.75
Avg(ŜE) 0.24 0.24 0.24 0.22 0.36 0.52 0.51 0.77 6.05
95% CP 94.9 94.8 95.8 95.0 94.8 94.9 93.9 95.0 97.4
500 Bias 0.02 0.01 0.00 0.01 0.02 -0.03 0.00 0.02 -0.19
SD(β̂) 0.15 0.16 0.14 0.14 0.22 0.32 0.28 0.44 0.96
Avg(ŜE) 0.15 0.15 0.15 0.14 0.22 0.31 0.28 0.43 0.81
95% CP 94.9 94.4 95.3 95.9 94.6 94.9 95.7 95.1 96.1
SD(β̂): Empirical standard deviation of estimated β̂ coefficients
Avg(ŜE): Average of 1000 estimated standard errors (using Hessian matrix)
95% CP: 95% coverage probability.
The simulation results are summarized in Table 4.1. The estimated log-hazard-
ratios (LHRs) for time-to-response and time-to-death were very close to the true
β. The averaged estimated standard errors were consistent with empirical standard
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errors of β̂. Both were smaller as sample size increased. The only discrepency
was with the interaction term between V and regimen A2B2 (βη = −2.4) in the
smaller sample size (n=200). This is understandable because of our setup with equal
treatment randomization probabilities and the distribution of V, only 18.75% of the
sample experienced this interaction effect (∼ 37 individuals). At sample size n=500,
the interaction was adequately estimated.
4.3.2 Predicted survival rates: Comparison of the joint model with existing methods
As noted in Section 4.1, a DTR includes both responders and non-responders
that are consistent with the regimens. In design II, regimen {A1B1C1} includes
the A1 responders who get B1 and the A1 non-responders who get C1. However,
traditional Kaplan-Meier estimation based on the combined sample of these two
subgroups is biased because it overweights the non-responders. To correct for this
bias, the responders who receives B1 have to represent themselves and be up-weighted
to account for those that are re-randomized to B2. The same bias has to be corrected
in design I if randomization probabilities P or Q are not balanced (1/2 for each
treatment arm).
Lunceford et al. (2002) corrected this bias by using the randomization probabil-









. Patients who died before response were classified as
non-responders. Using these inverse probability weights, they proposed a survival
estimator for each regimen as












(Wjkli − 1), (4.6)
where K̂(t) is the Kaplan-Meier estimate from censoring time to adjust for censored
patients and α is chosen so that the estimator has minimum variance.
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making the weighting scheme time dependent. This means that before the time of
response, responders to A1 who would eventually be re-randomized to B2 were also
consistent with regimen A1B1C1. Using this weight, they proposed the weighted risk
set estimator (WRSE) for the survival of regimen AjBkCl as follows:










It is easy to see that if we ignore weights Wjkl and K̂(t), IPWE is the proportion
of subjects that have not yet failed before t, and WRSE is a Nelson-Aalen survival
estimator. The disadvantage of both estimates is that they can not be adjusted for
auxiliary covariates such as V , only that one can perform subset analyses for different
values of V .
Tang and Wahed (2015) proposed a model based on Cox with IPW that can
incorporate baseline covariates. Using their proposed cumulative hazards, we calcu-
lated the survival prediction for each DTR and compared it against our model in the
following simulation.
The advantage of our proposed joint model is that not only do we have a model
to parameterize how auxiliary covariates and treatments in each stage affect time-
to-response and time-to-death and their interaction, but also that we can derive
closed-form expressions for the marginal survival function (eq. 4.8) of each DTR,
analogous to eq.(4.6) and (4.7), without having to reconfigure the weighting scheme
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frSd(r, t)dr + SrSd(t, t), t < t
nr∫ tnr
0
frSd(r, t)dr + SrSd(t
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Figure 4.2: Estimated survival probabilities for 4 DTRs in Design II: Joint modeling (solid lines,
eq. 4.8) compared with IPWE (gray dashed lines, eq. 4.6) and WRSE (black dashed
lines, eq. 4.7).
Figure 4.2 plots the survival estimates for the four DTRs in Design II using our
proposed model and non-parametric estimators from Lunceford et al. (2002) and Guo
and Tsiatis (2005). The solid lines denote our model survival prediction conditioning
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on regimen and baseline covariate V (eq. 4.8). The gray and black dashed lines
denote the IPWE (eq. 4.6) and WRSE (eq. 4.7), respectively. The latter two
estimators do not have a way to adjust for baseline V , thus only provide an overall
prediction for each regimen.
It is easy to see that the ability to adjust for auxiliary covariates such as V at
baseline hazards (and potentially other relevant covariates at second randomization)
is important. In the top left panel of Figure 4.2, the effect of reigmen A1B1C1
is identical for both subgroups of V , thus our survival prediction conditioning on V
overlaps that of IPWE and WRSE. However, this is not the case for regimensA1B2C1,
A2B1C1, and A2B2C1. We can see that different strata of V react differently to these
regimens. Group V = 0 had the highest survival rates from A2B1C1, while group
V = 1 benefited from A2B2C1. This information would be lost if we ignored V
and used IPWE and WRSE, where the best conclusion would be that A2B1C1 and
A2B2C1 were equally optimal for the whole population on average. If we average our
model’s survival prediction over V , we get consistent prediction with WRSE. IPWE,
on the other hand, does not perform well for A2B2C1 regimen (Figure 4.2 bottom
right, gray dashed line). This is because the weights in IPWE are time-independent,
thus ignoring the information from people who receive A2B1C1 (e.g. assigning weight
0) in the survival estimate for A2B2C1. WRSE, on the other hand, assigns non-zero
weight for A2B1C1 during the period before second randomization (i.e. when only
A2 is administered). Our joint model naturally achieves this advantage of WRSE.
Regardless, only our proposed model is able to handle situations with multiple and/or
continuous auxiliary covariates where subset analysis is not feasible.
We should note that in special cases where V is categorical with a small number of
subgroups, IPWE and WRSE can adjust for V by subset analysis. In such cases, our
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model’s prediction is consistent with the survival predictions from subset analysis
using IPWE and WRSE (see Appendix C.3 for simulation results).















































Figure 4.3: Methods by Tang and Wahed (2015) cannot adjust for interactions between V and
regimens (left plot). The proposed joint model’s predictions are consistent with subset
analysis using WRSE (right plot).
Unlike our joint model, the Cox model proposed by Tang and Wahed (2015)
only performs well under certain conditions. Even though this model can adjust for
baseline covariates V , it requires the assumption that the effect of V is constant across
different DTRs (i.e. there is no interaction between covariates V and regimens). In
simulations where there this is the case, the survival prediction from Tang and Wahed
(2015) is consistent with our joint model (Appendix C.3). However, when different
V subgroups have different optimal DTRs, only our model’s predictions and subset
analyses of WRSE (when categorical) remain consistent. The model in Tang and
Wahed (2015) fails to account for the interaction between covariates and treatment
which leads to the inaccurate survival predictions shown in the left plot of Figure
4.3.
70
4.4 Multiple comparisons with the best (MCB)
4.4.1 Methods
Many DTRs are embedded within a SMART, and often the comparisons between
DTRs are of interest. For example, there are four embedded DTRs in design II
leading to six pairwise comparisons. Design I has eight DTRs leading to potentially
28 pairwise comparisons. As the number of DTRs increases, standard comparison
methods begin to lose statistical power. The ultimate goal of a SMART may be to
identify the best DTR of all embedded DTRs or to find a set of best DTRs if their
differences are minimal. Multiple comparisons with the best (MCB) (Hsu, 1996)
was introduced to address this issue in SMART with continuous outcomes (Ertefaie
et al., 2016), but this method has not been extended to address survival outcomes
in the SMART setting.
For ease of notation, we use Ŝm to denote Ŝ(t) for DTR m, where m = 1, . . . ,M
and t is the time at which we want to compare all DTR survival probabilities. Let B
be the set of DTRs that results in best Ŝ(t) and others that can not be differentiated
from the former at a certain threshold c. If we plot the survival rate from each DTR
at a particular time of interest (Figure 4.4), regimen l with highest survival rate
should be selected for inclusion in set B. Regimen m that is very close to the best
is also of interest (e.g. it may be less expensive, easier to administer, or have fewer
side effects). Therefore, we want to implement MCB to identify regimens within a
distance c from the best one.
The steps to find cm, the threshold for each regimen m, are as follows: Since
regimens with different first-line treatments are independent, their covariances are 0.





















⇒ m ∈ B̂
Figure 4.4: Multiple comparisons with the best





where Σ1 is the covariance matrix for Ŝ(t) from DTRs that start with first-line
treatment A1 and Σ2 is from DTRs that start with A2. In design I, Σ1 and Σ2 are
4× 4 matrices. In design II, they are both 2× 2. In design III, Σ1 is 2× 2 and Σ2 is
a scalar. Denote σm,l the element of Σ1 and Σ2 (i.e. the covariance between Ŝm(t)
and Ŝl(t)).
The set of best DTRs is B̂ = {m | (Ŝm − Ŝl)/σ?ml ≥ cm,∀l 6= m}, where
σ̂?ml =
√




l − 2σ̂m,l). (4.10)
A natural choice for cm is a value that satisfies α Type 1 error rate (i.e. if the
differences between DTRs are 0, each has (1 − α) chance of being included in B̂).
Then cm satisfies
1− α =P (Zm ≥ Zl − cmσ?ml,∀l 6= m)













where Z1, . . . , ZM are MVN(0,Σ), and φ(z) is the CDF of Zm. The procedure to find
cm is adapted from the procedure used for SMART data with continuous outcomes
(Ertefaie et al., 2016):
1. Estimate the boostrapped covariance matrix Σ̂ between DTR survival rates at
any time t of interest.
2. Simulate B = 1000 samples of Z1b, . . . , ZMb ∼ MVN(0, Σ̂).
3. For each b = 1, . . . , B, calculate maxl 6=m [(Zlb − Zmb)/σ?ml], where σ?ml can be
calculated from Σ̂ and eq.(4.10).
4. cm is the (1− α)th quantile of the (1×B) vector found in previous step.
4.4.2 Simulation study
We applied MCB to simulated data from SMART design II with four possible
DTRs. Implementation of MCB for designs I and III is identical.
The parameters are as follows: sample size was 500; randomization probabilities
was set to 0.5 for both first-line X and second-line treatments Zr; censoring time
C ∼ Unif(0, 20). The hazard of response was λr(t) = hr(t) exp{δX}, where hr(t) ∼
Weibull(0.75, 4). With hd(t) ∼Weibull(3, 4), the hazard of death was
λd(t) = hd(t) exp
{









When δ = 0, all four DTRs were equally effective. As δ increased, the individuals
following DTR A2B2C1 (X = 1, Z
r = 1) responded faster and had lower risk of
death (both before and after response) compared to those following other DTRs.
For each δ between 0 and 2, we simulated 500 datasets and applied MCB to identify
the set of best DTRs. Using survival rates at time t = 7 and t = 15 as the metric of





























Figure 4.5: MCB selection for simulated SMART design II: the y-axis is the expected size of best
DTRs set (ESS) and x-axis is various values of δ.
Figure 4.5 shows the probabilities that each of the four DTRs was chosen to be in
the set of “best” DTRs for different δ values. The sum of these probabilities is the
expected size of set B̂ (ESS). As expected, ESS converged to 1 as treatment effect δ
gets larger. At δ = 0, all regimens were equally beneficial; thus all four DTRs were
chosen to be included in B̂. As δ increased, A2B2C1 became the optimal regimen
with the lowest risk of death, making B̂ a set of size 1. If interest is in the comparison
of DTRs at time 7, the left plot shows MCB results using survival rates at this time.
ESS quickly converged to 1 with A2B2C1 being the chosen regimen. The right plot
compares DTRs at a later time, t = 15, where for δ < 1.3, most patients died before
time 15 and all four DTRs were comparable. At larger δ, A2B2C1 had better survival
rates compared to the other three DTRs.
4.5 Discussion
We proposed a joint modeling framework to evaluate dynamic treatment regimens
embedded in a SMART. Previously proposed methods for data from a SMART with
survival outcomes employ inverse probability weighting and either treat survival
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time as a continuous outcome or compare survival rates between DTRs using non-
parametric estimators. Our proposed model is based on Cox models with flexible non-
parametric baseline hazards for time-to-response and time on second-line treatment.
We demonstrated that our model provides equally unbiased surival estimates as the
non-parametric methods, while offering many other advantages.
Compared to the non-parametric estimators, our model offers the following fea-
tures: (i) adjusts for auxiliary covariates that includes not only baseline information
but also potentially new covariates at the end of first-line treatment, (ii) has a mech-
anism to parameterize/measure each treatment’s effect within the regimen, their in-
teractions, and interactions with auxiliary covariates (without assumptions of these
effects within or between DTRs), (iii) easy adaptation between different SMART de-
signs by setting certain β’s to 0, and (iv) the ability to estimate conditional survival
functions conditioning on not only the particular DTR of interest, but also on what
has been observed so far (e.g. Ŝ(t | response at s) or Ŝ(t | no response by s)).
The limitation of our model is that the non-parametric estimation of baseline
hazards requires larger sample sizes (depending on the total number of unique time-
points from all subjects in the data) and longer computational time compared to
other models where a distribution is assumed. If only a small sample size is avail-
able, we can fit our model assuming some parametric distributions for the baseline
hazards (e.g. Weibull). This will decrease the number of parameters needed to be
estimated, yet still offers all of the advantages discussed.
The issue of multiple comparisons has not been fully addressed for survival data
in the SMART setting. In order to identify the optimal DTR(s), SMARTs with
many embedded DTRs may require a large number of comparisons resulting in a
loss of statistical power. We adapt the previously proposed approach using multiple
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comparisons with the best for continous outcomes to compare DTRs with survival
outcomes. We compare each DTR’s predicted survival rate at time t with the best of
others, then identify a set of DTRs that contains the true best DTR with a certain
type I error rate. We outlined the procedure to find rejection rule that would satisfy
such type I error and demonstrated the method with simulations.
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CHAPTER V
Conclusions and Future Work
This dissertation presented joint models that simultaneously analyze multiple
time-to-events, where events are related stages in two settings: cancer progression
stages (latent metastasis, observed diagnosis and death) and sequential rounds of
treatment in a SMART.
In chapter II, we presented a joint model of time-to-diagnosis, time-to-metastasis,
and time-to-death motivated by prostate cancer progression. Assuming the same
underlying biological cause drives the non-terminal and terminal events, previously
proposed joint models used the same baseline hazard for a series of nested propor-
tional hazard models to construct the joint likelihood of the entire disease timeline
(Hu and Tsodikov, 2014a). This assumption assists the incorporation of latent events
(e.g. closed-form integration of interval censored metastasis status), but it is too re-
strictive as the number of disease stages increases (e.g. three stages in the prostate
cancer analysis, section 2.4). To address this problem without compromising compu-
tational efficiency and a mechanism to relate the risk of one event to another, the joint
model in chapter II estimated the baseline hazards for one stage non-parametrically
and for other stages using parametric transformations of the former. Extension to
handle latent disease stages where a change in status is only known at a certain time
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points (e.g. metastasis status at diagnosis time) is also demonstrated.
The removable pathways in constructing the joint likelihood further makes the
proposed model adapatable to describe different disease processes. In some cancers,
death occurs after metastasis. In others, death may occur at any point after di-
agnosis. To model the latter, an additional term to the likelihood can reflect the
possibility of a patient dying without intermediate stages, while the estimation pro-
cedure remains the same. This can also be generalized to model different segments
of the diseases, such as the time between recurrence and death.
Chapter III was motivated by the need to model the observed adversed effect
of early diagnosis age on breast cancer survival. We extended the joint model in
chapter II to allow for multiple non-parametric baseline hazards and an additional
common latent frailty term to capture the unaccounted dependence between cancer
stages. The model can be adapted to allow for different sets of covariates, both
time-dependent and time-independent, at each stage. Due to the complexity of the
joint modeling and non-parametric component, the NPMLE estimation can be time-
consuming, but incorporating C++ via R package “Rcpp” speeds up the process
significantly.
Future research in this area includes modeling recurring stages, partial missing-
ness, incorporating screening history, and competing risks due to death from other
causes. More consideration regarding the intepretation of the treatment effect in
analysis of observational data is also needed. As treatment assignment is not known
during pre-diagnosis stages in the disease progression, it can be argued to be depen-
dent on the patient’s underlying disease process and thus cannot be used as external
covariates. Development to speed up the estimation procedure would also help make
this joint modeling approach more attractive to researchers.
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In chapter IV, the joint modeling approach was applied to survival data from a
SMART. Compared to previously proposed methods, this approach can adjust for
auxiliary covariates beside treatments (e.g. baseline covariate and new covariates
at second randomization). It also provides a mechanism to parameterize treatment
effects within the regimen and interactions between treatment and covariates. Sim-
ulations show that the proposed joint model allows for flexible modeling of various
interactions between treatments and auxiliary covariates. This model benefits re-
searchers because accurate conditional survival predictions can be used to inform
treatment decisions for ongoing patients. As individualized treatment and SMART
designs gain popularity, joint models offer an approach that can be tailored to many
settings with different types of outcomes. Its application to study treatment regi-
mens can be extended to SMART with more than two stages. Additional research





Supplementary Materials for Chapter II
A.1 Derivation of likelihood terms
For ease of notation, we suppress the subscript i for each individual subject. The
likelihood for different scenarios of diagnosis, metastasis, and death are:
• Subject is diagnosed without metastasis at t1, metastasizes, and dies at t2:






































• Subject is diagnosed without metastasis at t1 and is censored at t2
L∗2(t1, t2) = P (T ∗1 = t1, T ∗2 > t2, Tu > t2) + P (T ∗1 = t1, T ∗2 > t2, t1 < Tu < t2)




















































• Subject is diagnosed with metastasis at t1 and dies at t2










































• Subject is diagnosed with metastasis at t1 and is censored at t2







































• Subject is censored at t1 before any event is observed










































A.2 Derivation of hazard terms
For ease of notation, we suppress the subscript i for each individual subject.
1. The probability of diagnosis at time t:
• If diagnosed before metastasis
Θ1(Ht, β)dHt = Pr[dN
−
1 (t) = 1 | Y1(t) = 1] = L1/L5

















• If diagnosed after metastasis
Θ1(Ht, β)dHt = Pr[dN
+
1 (t) = 1 | Y1(t) = 1] = L3/L5
























2. The probability of death at time t:
• If diagnosed without metastasis at time t1 prior to t
Θ2(Ht, β, t1)dHt = Pr[dN
−
2 (t) = 1 | Y −2 (t) = 1] = L̃1/L̃2 = L?1/L?2
























• If diagnosed with metastasis at time t1 prior to t
Θ2(Ht, β, t1)dHt = Pr(dN
+
2 (t) = 1 | Y +2 (t) = 1) = L̃3/L̃4 = L?3/L?4






A.3 Proof of Martingale Properties:







































































ε2i(u, t; β,H, t1i)dM2i(u),
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which equal 0 if ε′(u, t) = ∂ε(u,t)
∂t
= 0 for u ≤ t (true by definition).
Therefore, the score function Uβ and UHt are both martingales at the true model.
A.4 Profile likelihood Hessian
The following proof to justify the use of Hessian matrix to estimate the standard
errors of β is based on (Rice and Tsodikov, 2016, Appendix F).
























Q = Iββ − IβHI−1HHIHβ. (A.3)
Denote by JHβ the Jacobian
∂dĤβ(s)
∂β













so that the profile score is
Upr = UĤβJHβ + Uβ|H=Ĥβ = Uβ|H=Ĥβ (A.4)
since UĤβ = 0.
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= −JβH ÎHHJHβ + UĤβJHβHJHβ − ÎβHJHβ − JβH ÎHβ + UĤβJHββ − Îββ.
Since UĤβ = 0, we have
1pr = JβH ÎHHJHβ + ÎβHJHβ + JβH ÎHβ + Îββ (A.5)



















= −ÎHβ − ÎHHJHβ,
implying that
JHβ = −Î−1HH ÎHβ. (A.6)
Substitution of (A.6) into (A.5) yields

















= Îββ + ÎβH Î
−1
HH ÎHβ − 2ÎβH Î−1HH ÎHβ
= Îββ − ÎβH Î−1HH ÎHβ. (A.7)
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= Q−1 = 1pr−1.
A.5 Simulation not included in main paper
A.5.1 Smaller sizes needed when δ1 = δ2 = 1
When δ1 = δ2 = 1, we can solve the integral in Θ1 and Θ2 mathematically instead
of using numerical summation, thus estimation accuracy can be achieved at smaller
sample sizes. We performed 1000 repetitions with sample sizes 250 and 500. Each
scenario included covariates Z1 ∼ U(0, 5) and an increasing or decreasing baseline
hazard following a Weibull distribution ht = 0.02t (increasing) or ht = 0.05(t/10)
−1/2
(decreasing). Time-to-metastasis-onset, time-to-diagnosis, and time-to-death were
generated under Cox proportional hazards using parameters βη = 0.9, βθ = [0.5, 0.8],
βµ = [0.5, 0.6], and βγ = [0.1, 0.7].
Independent censoring time followed a uniform distribution U(0, 20) for the in-
creasing hazard and U(0, 10) for the decreasing hazard scenario, which yielded ap-
proximately 15% censoring before the first event (diagnosis) and 30% censoring before
the second event (death). The convergence criterion was set at 10−5 for a change in
the baseline hazard estimation and improvement in the full likelihood.
The simulation results are summarized in Table A.1. The iterative reweighting
algorithm works well for both scenarios of increasing and decreasing baseline hazards
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Table A.1: Simulation result: Independent censoring
Metastasis Diagnosis Death
N Statistics βη1 βθ0 βθ1 βµ0 βµ1 βγ0 βγ1
True 0.9 0.5 0.8 0.5 0.6 0.1 0.7
Increasing baseline hazard ht = 0.02t
200 Bias 0.013 0.023 0.008 0.061 0.006 -0.045 0.020
ESE 0.094 0.312 0.088 0.740 0.380 0.433 0.096
ASE 0.093 0.301 0.087 0.742 0.332 0.437 0.095
CP(%) 94.2 94.8 95.7 95.5 94.4 95.7 95.1
500 Bias 0.006 0.003 0.006 0.027 -0.004 -0.021 0.007
ESE 0.059 0.190 0.058 0.471 0.223 0.276 0.058
ASE 0.058 0.188 0.054 0.449 0.200 0.271 0.058
CP(%) 94.1 94.6 92.7 94.8 93.5 95.4 95.7
Decreasing baseline hazard ht = 0.05(t/10)
−1/2
200 Bias 0.003 -0.021 0.010 0.004 0.032 -0.064 0.018
ESE 0.094 0.295 0.083 0.741 0.371 0.454 0.094
ASE 0.094 0.291 0.085 0.790 0.346 0.448 0.092
CP(%) 94.7 94.6 95.8 96.1 94.0 94.7 94.8
500 Bias 0.004 0.002 0.005 -0.010 0.004 -0.010 0.005
ESE 0.058 0.188 0.055 0.497 0.219 0.296 0.057
ASE 0.059 0.183 0.053 0.473 0.206 0.281 0.057
CP(%) 95.6 94.8 94.3 94.7 94.6 93.3 94.3
ESE: empirical standard errors based on 1,000 estimates
ASE: average of estimated standard errors
CP: 95% Coverage Probability
(not shown). The estimates for covariate effects on time-to-latent-metastasis, time-
to-diagnosis, and time-to-death are almost unbiased at small sample size (n=200)
and further reduce bias for larger sample size (n=500). The empirical standard
errors (ESE) are close to the mean of estimated theoretical errors (ASE), which
validate the performance of the variance estimators. Coefficient estimators improve
with increasing sample size as the estimated variances decrease and 95% confidence
intervals tighten. The 95% coverage probabilities for all coefficient estimators remain
as expected for both sample sizes.
A.5.2 Full simulation results when censoring time and survival time are dependent
This is the result of sensitivity analyses for dependent censoring discussed in
section 2.3.2. There are 16 covariates in this simulation, 5 of which are directly

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Materials for Chapter III
B.1 Derivation of likelihood probabilities
For ease of notation, we suppress the subscript i for each individual subject. The
likelihood for different scenarios of diagnosis, metastasis, and death are:
• Subject is diagnosed at t1:







• Subject is diagnosed at t1 and dies at t2:


















• Subject is diagnosed at t1 and is censored at t2














• Subject is censored at t1 before any event is observed









B.2 Derivation of hazard terms
1. The hazard of being diagnosed with cancer at time t:
Θ1[Hdx(t), β]dHdx(t) = P [dN1(t) = 1 | Y1(t) = 1] =
L1
L3









2. The hazard of death at time t, given diagnosis at t1:
















B.3 Martingale Properties of Nonparametric Maximum Likelihood Es-
timators














































































which equal 0 if ε′(u, t) = ∂ε(u,t)
∂t
= 0 for u ≤ t (true by definition).
Therefore, the score function UHdx(t) is martingale at the true model. The proofs
for Uβ and UHd(t) follow along the same line.





be the solutions to UHr = 0 and UHd = 0 for fixed β, we





is consistent for the covariance matrix of β̂, that
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Q = Iββ − IβHI−1HHIHβ. (B.4)
where IβH = [IβHdx IβHd ] and IHH is the bottom right 2× 2 matrix of I∞.




















so that the profile score is























































































= −JβH ÎHHJHβ + UĤβJHβHJHβ − ÎβHJHβ − JβH ÎHβ + UĤβJHββ − Îββ.
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Since UĤβ = 0, we have
Ipr = JβH ÎHHJHβ + ÎβHJHβ + JβH ÎHβ + Îββ (B.6)



















= −ÎHβ − ÎHHJHβ,
implying that
JHβ = −Î−1HH ÎHβ. (B.7)
Substitution of (B.7) into (B.6) yields

















= Îββ + ÎβH Î
−1
HH ÎHβ − 2ÎβH Î−1HH ÎHβ
= Îββ − ÎβH Î−1HH ÎHβ. (B.8)































= Q−1 = I−1pr .
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APPENDIX C
Supplementary Materials for Chapter IV
C.1 Derivation of likelihood probabilities
For ease of notation, we suppress the subscript i for each individual subject.
We assume Design II, but modifications for other designs are trivial (by includ-
ing/excluding treatment covariates in γ and µ). The likelihood for different scenarios
of response, non-response, and death are:
(1) Subject responds at t1, is re-randomized in stage 2, and dies at t2:












(2) Subject responds at t1, is re-randomized in stage 2, and is censored at t2:











(3) Subject does not respond by tnr, receives stage 2 treatment as a non-responder,
then dies at t2:
L3(t














(4) Subject does not respond by tnr, receives stage 2 treatment as a non-responder,
and is censored at t2:
L4(t













(5) Subject dies at t1 before the second randomization:











(6) Subject is censored at t1 before second randomization:
L6(t1) = SrSd(t1, t1) = e
−θHr(t1)−γHd(t1)
C.2 Martingale Properties of Nonparametric Maximum Likelihood Es-
timators
























































































































































which equal 0 if ε′(u, t) = ∂ε(u,t)
∂t
= 0 for u ≤ t (true by definition).
Therefore, the score function UHr(t) is martingale at the true model. The proofs
for Uβ and UHd(t) follow along the same line.
C.3 Simulations: No interaction effect between V and regimens
The model in Tang and Wahed (2015) can adjust for baseline covariates. However,
these covariates’ effects are constant across regimens. We simulate SMART survival
data under this assumption to compare this model’s predictive performance and
validate the survival predictions from our proposed model.
The simulation parameters are identical to those used in Section 4.3.1, but with
interaction term β9 = 0 (i.e. the effect of a baseline covariate V is the same across
96
different DTRs). Regimen A2B1C1 is the best for both V subgroups.
































































Figure C.1: Survival estimates in a scenario with no interaction between baseline covariate V and
regimens.
Figure C.1 plots the survival estimates for each DTR. The left plot is for V = 0
and the right plot is for V = 1. Our model’s estimates are solid lines. Tang and
Wahed (2015) estimates are long dashed lines. Subset analysis (by V ) using IPWE
and WRSE from Lunceford et al. (2002) and Guo and Tsiatis (2005) are plotted in
short dashed lines and dotted lines, respectively. We see that our model’s prediction
is consistent with those from previously proposed methods in scenarios where there
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J. Smolle, H. P. Soyer, F. Smolle-Jüttner, E. Rieger, and H. Kerl. Does surgical removal of pri-
mary melanoma trigger growth of occult metastases? an analytical epidemiological approach.
Dermatologic surgery, 23(11):1043–1046, 1997.
X. Tang and A. S. Wahed. Cumulative hazard ratio estimation for treatment regimes in sequentially
randomized clinical trials. Statistics in Biosciences, 7(1):1–18, 2015.
P. F. Thall, L. H. Wooten, C. J. Logothetis, R. E. Millikan, and N. M. Tannir. Bayesian and
frequentist two-stage treatment strategies based on sequential failure times subject to interval
censoring. Statistics in Medicine, 26(26):4687–4702, 2007.
A. Tsodikov. Semi-parametric models of long-and short-term survival: an application to the analysis
of breast cancer survival in utah by age and stage. Statistics in Medicine, 21(6):895–920, 2002.
A. Tsodikov. Semiparametric models: a generalized self-consistency approach. Journal of the Royal
Statistical Society: Series B (Statistical Methodology), 65(3):759–774, 2003.
A. S. Wahed. Inference for two-stage adaptive treatment strategies using mixture distributions.
Journal of the Royal Statistical Society: Series C (Applied Statistics), 59(1):1–18, 2010.
J. Xu, J. D. Kalbfleisch, and B. Tai. Statistical analysis of illness–death processes and semicom-
peting risks data. Biometrics, 66(3):716–725, 2010.
D. Zeng and D. Lin. Efficient estimation of semiparametric transformation models for counting
processes. Biometrika, 93(3):627–640, 2006.
D. Zeng, Q. Chen, and J. G. Ibrahim. Gamma frailty transformation models for multivariate
survival times. Biometrika, 96(2):277–291, 2009.
102
